NAYA Biosciences (NAYA) S-1/A 9 Sep 19 2019 Q2 IPO registration (amended) Financial data

Document And Entity Information

Document And Entity Information	6 Months Ended
	Jun. 30, 2019
Document Information Line Items
Entity Registrant Name	INVO Bioscience, Inc.,
Document Type	S-1
Amendment Flag	false
Entity Central Index Key	0001417926
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Current assets
Cash	$ 2,663,171	$ 212,243	$ 25,759
Accounts receivable net	240,214	225,899	86,697
Inventory, net	76,475	43,513	58,879
Prepaid expenses and other current assets	195,481	249,454	63,050
Total current assets	3,175,341	731,109	234,385
Property and equipment, net	98,109	34,446	15,700
Capitalized patents, net	9,502	11,792	16,328
Lease right of use, net	112,827	0	0
Total other assets	122,329	11,792	16,328
Total assets	3,395,779	777,347	266,413
Current liabilities
Accounts payable and accrued liabilities, including related parties	528,640	571,828	960,725
Accrued compensation	969,226	2,515,256	3,955,190
Deferred revenue	727,261	18,895	0
Current portion of lease liability	18,898	0	0
Note payable	0	97,743	210,888
Note payable - related party	35,000	131,722	0
Convertible notes, net of discount of $497,961	0	157,039	0
Convertible notes, related party - net of discount of $30,913	0	9,087	0
Total current liabilities	2,279,025	3,501,570	5,126,803
Note payable - long term	0	0	131,722
Commitments and contingencies (Note 12)
Lease liability	94,173	0	0
Deferred revenue	3,928,571	0	0
Convertible notes, net of discount	232,960	0	0
Convertible notes, net of discount – related party	20,072	0	0
Total liabilities	6,554,801	3,501,570	5,258,525
Stockholders’ deficiency
Preferred Stock, $.0001 par value; 100,000,000 shares authorized; No shares issued and outstanding as of June 30, 2019 and December 31 2018, respectively	0	0	0
Common Stock, $.0001 par value; 200,000,000 shares authorized; 155,546,112 and 154,292,497 and 142,132,374 issued and outstanding as of June 30, 2019 and December 31, 2018 and 2017, respectively	15,554	15,429	14,213
Additional paid-in capital	19,246,768	18,981,570	13,638,806
Accumulated deficit	(22,421,344)	(21,721,222)	(18,645,131)
Total stockholders’ deficiency	(3,159,022)	(2,724,223)	(4,992,112)
Total liabilities and stockholders' deficiency	$ 3,395,779	$ 777,347	$ 266,413

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)	Jun. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Convertible notes, discount (in Dollars)		$ 497,961
Convertible notes, related party - discount (in Dollars)	$ 24,089	$ 30,913	$ 0
Preferred Stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Preferred Stock, shares authorized	100,000,000	100,000,000	100,000,000
Preferred Stock, shares issued	0	0	0
Preferred Stock, shares outstanding	0	0	0
Common Stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Common Stock, shares authorized	200,000,000	200,000,000	200,000,000
Common Stock, shares issued	155,546,112	154,292,497	142,132,374
Common Stock, shares outstanding	155,546,112	154,292,497	142,132,374

CONSOLIDATED STATEMENTS OF LOSS

CONSOLIDATED STATEMENTS OF LOSSES - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Revenue	$ 658,638	$ 110,210	$ 848,070	$ 214,350	$ 494,375	$ 282,145
Cost of goods sold	55,282	16,710	66,260	31,134	90,367	51,954
Gross margin	603,356	93,500	781,810	183,216	404,008	230,191
Selling, general and administrative expenses	669,152	1,883,946	1,196,717	2,113,945	3,038,068	870,612
Total operating expenses	669,152	1,883,946	1,196,717	2,113,945	3,038,068	870,612
Loss from operations	(65,796)	(1,790,446)	(414,907)	(1,930,729)	(2,634,060)	(640,421)
Loss on settlement of debt	0	0	0	0	0	40,869
Interest expense	175,756	74,682	285,215	79,122	442,031	20,873
Total other ( income) expenses	175,756	74,682	285,215	79,122	442,031	61,742
Loss before income taxes	(241,552)	(1,865,128)	(700,122)	(2,009,851)	(3,076,091)	(702,163)
Provision for income taxes	0	0	0	0
Net loss	$ (241,552)	$ (1,865,128)	$ (700,122)	$ (2,009,851)	$ (3,076,091)	$ (702,163)
Basic net loss per weighted average shares of common stock (in Dollars per share)	$ 0	$ (0.01)	$ (0.01)	$ (0.01)	$ (0.02)	$ 0
Diluted net loss per weighted average shares of common stock (in Dollars per share)	$ 0	$ (0.01)	$ (0.01)	$ (0.01)	$ (0.02)	$ 0
Basic weighted average number of shares of common stock (in Shares)	155,260,947	147,316,458	154,873,694	145,339,696	147,333,051	141,305,050
Diluted weighted average number of shares of common stock (in Shares)	155,260,947	147,316,458	154,873,694	145,339,696	147,333,051	141,305,050
Product Revenue [Member]
Revenue	$ 480,067	$ 110,210	$ 490,927	$ 214,350
License Revenue [Member]
Revenue	$ 178,571		$ 357,143

CONSOLIDATED STATEMENT OF STOCK

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIENCY) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2016	$ 14,059	$ 13,311,263	$ (17,942,968)	$ (4,617,646)
Balance (in Shares) at Dec. 31, 2016	140,596,646
Common stock issued for cash	$ 32	54,593		54,625
Common stock issued for cash (in Shares)	318,056
Common stock issued for services	$ 88	215,044		215,132
Common stock issued for services (in Shares)	876,672
Discount on convertible notes payable				0
Conversion of notes payable and accrued interest	$ 34	57,906		57,940
Conversion of notes payable and accrued interest (in Shares)	341,000
Net loss			(702,163)	(702,163)
Balance at Dec. 31, 2017	$ 14,213	13,638,806	(18,645,131)	$ (4,992,112)
Balance (in Shares) at Dec. 31, 2017	142,132,374			142,132,374
Common stock issued for services				$ 43,664
Common stock issued for services (in Shares)				352,326
Balance at Mar. 31, 2018	$ 14,394	13,867,289	(18,789,854)	$ (4,908,171)
Balance (in Shares) at Mar. 31, 2018	143,944,700
Balance at Dec. 31, 2017	$ 14,213	13,638,806	(18,645,131)	$ (4,992,112)
Balance (in Shares) at Dec. 31, 2017	142,132,374			142,132,374
Common stock issued for cash	$ 41	76,959		$ 77,000
Common stock issued for cash (in Shares)	410,000
Common stock issued to directors and employees	$ 120	137,880		138,000
Common stock issued to directors and employees (in Shares)	1,200,000
Common stock issued for services	$ 371	1,758,093		1,758,464
Common stock issued for services (in Shares)	3,712,326
Discount on convertible notes payable		895,000		895,000
Net loss			(2,009,851)	(2,009,851)
Balance at Jun. 30, 2018	$ 14,745	16,506,738	(20,654,982)	(4,133,499)
Balance (in Shares) at Jun. 30, 2018	147,454,700
Balance at Dec. 31, 2017	$ 14,213	13,638,806	(18,645,131)	$ (4,992,112)
Balance (in Shares) at Dec. 31, 2017	142,132,374			142,132,374
Common stock issued for cash	$ 41	76,959		$ 77,000
Common stock issued for cash (in Shares)	410,000
Common stock issued to directors and employees	$ 678	2,316,555		2,317,233
Common stock issued to directors and employees (in Shares)	6,782,382
Common stock issued for services	$ 391	1,843,273		1,843,664
Common stock issued for services (in Shares)	3,912,326
Discount on convertible notes payable		895,000		895,000
Conversion of notes payable and accrued interest	$ 106	210,977		211,083
Conversion of notes payable and accrued interest (in Shares)	1,055,415
Net loss			(3,076,091)	(3,076,091)
Balance at Dec. 31, 2018	$ 15,429	18,981,570	(21,721,222)	$ (2,724,223)
Balance (in Shares) at Dec. 31, 2018	154,292,497			154,292,497
Balance at Mar. 31, 2018	$ 14,394	13,867,289	(18,789,854)	$ (4,908,171)
Balance (in Shares) at Mar. 31, 2018	143,944,700
Common stock issued for cash	$ 15	29,985		30,000
Common stock issued for cash (in Shares)	150,000
Common stock issued for services	$ 336	1,714,464		1,714,800
Common stock issued for services (in Shares)	3,360,000
Discount on convertible notes payable		895,000		895,000
Net loss			(1,865,128)	(1,865,128)
Balance at Jun. 30, 2018	$ 14,745	16,506,738	(20,654,982)	(4,133,499)
Balance (in Shares) at Jun. 30, 2018	147,454,700
Balance at Dec. 31, 2018	$ 15,429	18,981,570	(21,721,222)	$ (2,724,223)
Balance (in Shares) at Dec. 31, 2018	154,292,497			154,292,497
Common stock issued for services	$ 6	26,594		$ 26,600
Common stock issued for services (in Shares)	60,000
Conversion of notes payable and accrued interest	$ 119	238,604		238,723
Conversion of notes payable and accrued interest (in Shares)	1,193,615
Net loss			(700,122)	(700,122)
Balance at Jun. 30, 2019	$ 15,554	19,246,768	(22,421,344)	$ (3,159,022)
Balance (in Shares) at Jun. 30, 2019	155,546,112			155,546,112
Balance at Mar. 31, 2019	$ 15,461	19,061,861	(22,179,792)	$ (3,102,470)
Balance (in Shares) at Mar. 31, 2019	154,621,112
Conversion of notes payable and accrued interest	$ 93	184,907		185,000
Conversion of notes payable and accrued interest (in Shares)	925,000
Net loss			(241,552)	(241,552)
Balance at Jun. 30, 2019	$ 15,554	$ 19,246,768	$ (22,421,344)	$ (3,159,022)
Balance (in Shares) at Jun. 30, 2019	155,546,112			155,546,112

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Net loss	$ (700,122)	$ (2,009,851)	$ (3,076,091)	$ (702,163)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on settlement of debt	0	0	0	40,869
Adjustments to reconcile net loss to net cash provided by operating activities:
Non-cash stock compensation issued for services	26,600	1,743,464	2,092,664	215,132
Amortization of discount on notes payable	256,703	56,446	366,126	0
Amortization of leasehold right of use asset	3,614
Depreciation and amortization	3,465	2,268	5,190	2,810
Changes in assets and liabilities:
Accounts receivable	(14,315)	(52,696)	(139,202)	(83,903)
Inventories	(32,962)	(522)	15,366	26,331
Prepaid expenses and other current assets	53,974	21,619	200,596	(52,070)
Deferred revenue	4,636,937	0	18,895	0
Accounts payable and accrued expenses	1,280	(167,131)	(377,814)	(5,346)
Leasehold liability	(3,370)
Accrued interest - related party	24,458	0	0	(1,730)
Accrued compensation	(1,546,030)	156,900	241,299	378,800
Net cash provided by (used in) operating activities	2,710,232	(249,503)	(652,971)	(181,270)
Payments to acquire property, plant and equipment	(64,839)	0	(19,400)	0
Net cash (used) in investing activities	(64,839)	0	(19,400)	0
Cash from financing activities:
Proceeds from the sale of common stock	0	47,000	47,000	54,625
Proceeds from the sale of common stock - related parties	0	30,000	30,000	0
Proceeds from convertible notes payable	0	855,000	855,000	0
Proceeds from convertible notes payable - related parties	0	40,000	40,000	0
Principal payments on note payable - related parties	(62,743)	(28,000)	(113,145)	0
Cash paid for notes payable	(131,722)	0	0	0
Net cash (used in) provided by financing activities	(194,465)	944,000	858,855	54,625
Increase (decrease) in cash and cash equivalents	2,450,928	694,497	186,484	(126,645)
Cash and cash equivalents at beginning of period	212,243	25,759	25,759	152,404
Cash and cash equivalents at end of period	2,663,171	720,256	212,243	25,759
Interest	9,823	0	6,071	0
Taxes		912	912	912
Leasehold right of use asset and leasehold liability upon adoption of ASU 2016-02, lease (Topic 842)	116,441
Common stock issued for conversion of notes payable and accrued interest	$ 238,723	0	211,083	57,940
Common stock issued for prepaid services		153,000	387,000	0
Beneficial conversion feature on convertible notes		$ 895,000	895,000	0
Common stock issued for accrued compensation			$ 1,681,233	$ 0

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2019
Disclosure Text Block [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1 – Basis of Presentation The accompanying unaudited condensed consolidated balance sheets as of June 30, 2019 and December 31, 2018, the condensed consolidated statements of operations and stockholders’ deficiency for the three and six months ended June 30, 2019 and 2018, and cash flows for the six months ended June 30, 2019 and 2018 of INVO Bioscience, Inc. (the “Company”), and the related information contained in these notes have been prepared by management and are unaudited. In the opinion of management, all adjustments (which include normal recurring and nonrecurring items) necessary to present fairly the Company’s financial position, results of operations and cash flows in conformity with generally accepted accounting principles for the periods presented have been made. Interim operating results are not necessarily indicative of operating results for a full year. The preparation of our unaudited condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Certain information and note disclosures normally included in the Company’s annual consolidated financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s December 31, 2018 Annual Report on Form 10-K previously filed by the Company with the Securities and Exchange Commission (SEC). The Company considers events or transactions that have occurred after the unaudited condensed consolidated balance sheet date of June 30, 2019, but prior to the filing of the unaudited condensed consolidated financial statements with the SEC on this Quarterly Report on Form 10-Q, to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure, as applicable. Subsequent events have been evaluated through the date of the filing of this this Registration Statement on Form S-1, as amended, with the SEC.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2019
ASU 2018-12 Transition [Abstract]
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]	Note 2 – Recent Accounting Pronouncements Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of accounting standards updates (“ASUs”) to the FASB’s Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. ASUs not listed below were assessed and determined not to be applicable or are expected to have minimal impact on the Company’s consolidated financial position and results of operations. Recently Adopted Accounting Pronouncements In February 2016, FASB issued ASU 2016-02, Leases (“ASU 2016-02”). The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company adopted the standard effective January 1, 2019. The standard allows a number of optional practical expedients to use for transition. The Company choose the certain practical expedients allowed under the transition guidance which permitted us to not to reassess any existing or expired contracts to determine if they contain embedded leases, to not to reassess our lease classification on existing leases, to account for lease and non-lease components as a single lease component for equipment leases, and whether initial direct costs previously capitalized would qualify for capitalization under FASB ASC 842. The new standard also provides practical expedients and recognition exemptions for an entity's ongoing accounting policy elections. The Company has elected the short-term lease recognition for all leases that qualify, which means that we do not recognize a ROU asset and lease liability for any lease with a term of twelve months or less. The most significant impact of adopting the standard was the recognition of ROU assets and lease liabilities for operating leases on the Company's consolidated balance sheet but it did not have an impact on the Company's consolidated statements of operations or consolidated statements of cash flows. The Company did not have a cumulative effect on adoption prior to January 1, 2019.

Going Concern

Going Concern	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	Note 3 – Liquidity On January 14, 2019, INVO Bioscience entered into a distribution agreement (the “Distribution Agreement”) with Ferring International Center S.A. (“Ferring”) granted to Ferring exclusive licensing rights to sublicense the Company’s INVOcell together with the retention device. Under the terms of the Distribution Agreement, Ferring was obligated to make an initial payment to the Company of $5,000,000 upon satisfaction of certain closing conditions. The Company received the initial $5 million cash payment upon the execution of the Ferring distribution agreement in January 2019 and as a result believes its cash on hand will be sufficient to fund its current debt obligations, estimated capital expenditures and working capital needs for the next twelve months.	NOTE 2 GOING CONCERN The Company commenced operations in December 2008. During the year ended December 31, 2018, the Company had a net loss of $3,076,000 and cash used in operations of $653,000. At December 31, 2018, the Company had a working capital deficiency of $2,770,000 and a stockholder deficiency of $2,724,000. This raises substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to raise additional capital and implement its business plan.

Inventory

Inventory	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	Note 4 – Inventory As of June 30, 2019, and December 31, 2018, the Company recorded the following inventory balances: June 30, 2019 December 31, 2018 Work in Process $ 71,469 $ 30,689 Finished Goods 5,006 12,824 Total Inventory, net $ 76,475 $ 43,513	NOTE 3 INVENTORY The Company had inventory in the following amounts: December 31, 2018 December 31, 2017 Work in Process $ 30,689 $ 24,357 Finished Goods 12,824 34,522 Total Inventory $ 43,513 $ 58,879

Property and Equipment

Property and Equipment	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	Note 5 – Property and Equipment The estimated useful lives and accumulated depreciation for furniture, equipment and software are as follows as of June 30, 2019 and December 31, 2018: Estimated Useful Life Molds and Office Equipment 3 to 10 years June 30, 2019 December 31, 2018 Manufacturing Equipment- Molds $ 132,513 $ 70,363 Office Equipment 2,689 - Accumulated Depreciation (37,093 ) (35,917 ) Total $ 98,109 $ 34,446 During the three months ended June 30, 2019 and 2018 the Company recorded depreciation expense of $39 and $0, respectively. During the six months ended June 30, 2019 and 2018 the Company recorded depreciation expense of $1,176 and $0, respectively. The Company began shipping its new retention device in August 2018 which triggered the start of depreciating our retention device mold during the quarter.	NOTE 4 PROPERTY AND EQUIPMENT The estimated useful lives and accumulated depreciation for furniture, equipment and software are as follows: Estimated Useful Life Molds 3 to 7 years December 31, 2018 December 31, 2017 Manufacturing Equipment- Molds $ 70,363 $ 50,963 Accumulated Depreciation (35,917 ) (35,263 ) $ 34,446 $ 15,700 The Company recorded $654 and $0 depreciation expense in 2018 and 2017 as its earlier equipment was fully depreciated.

Patents

Patents	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Disclosure Text Block [Abstract]
Intangible Assets Disclosure [Text Block]	Note 6 – Patents As of June 30, 2019, and December 31, 2018, the Company recorded the following patent balances: June 30, 2019 December 31, 2018 Total Patents $ 77,722 $ 77,743 Accumulated Amortization (68,220 ) (65,951 ) Patent costs, net $ 9,502 $ 11,792 During the three ended June 30, 2019 and 2018, the Company recorded $1,455 and $1,134 in amortization expenses respectively. During the six ended June 30, 2019 and 2018, the Company recorded $2,269 and $2,268 in amortization expenses respectively. Estimated amortization expense as of June 30, 2019 is as follows: Years ended December 31, 2019 – remaining six months $ 2,268 2020 1,809 2021 1,809 2022 and thereafter 3,616 Total $ 9,502	NOTE 5 PATENTS The Company capitalizes the initial expense related to establishing the patent by country and then amortizes the expense over the life of the patent, typically 20 years. It then expenses annual filing fees to maintain the patents. The Company regularly reviews the value of the patent in the market place in proportion to the expense it must spend to maintain the patent. The Company has recorded the following patent costs: December 31, 2018 December 31, 2017 Total Patents $ 77,743 $ 77,743 Accumulated Amortization (65,951 ) (61,415 ) Patent costs, net $ 11,792 $ 16,328 The Company recorded amortization expense as follows: Twelve Months Ended December 31, 2018 2017 $ 4,536 $ 2,810 In 2011, the decision was made to not to pay the renewal fees and expedite the amortization of the original patent which expired in 2012. It was also decided to not spend its limited funds in defending the INVO Block patent as it only has value to the Company. The Company continues to pay the annual renewal fees on its active patents. Estimated amortization expense as of December 31, 2018 is as follows: Years ended December 31, 2019 $ 4,536 2020 1,809 2021 1,809 2022 1,809 2023 and thereafter 1,829 Total $ 11,792

Leases

Leases	6 Months Ended
	Jun. 30, 2019
Disclosure Text Block [Abstract]
Lessor, Operating Leases [Text Block]	Note 7 - Leases The Company has an operating lease for our facility, which have remaining terms 5 years with an option to renew for 3 additional years. They also do not have an early termination clause included. Our operating lease agreements do not contain any material restrictive covenants. As of June 30, 2019, the Company's lease components included in the consolidated balance sheet were as follows: Lease component Classification June 30, 2019 Assets ROU assets - operating lease Other assets $ 112,827 Total ROU assets $ 112,827 Liabilities Current operating lease liability Current liabilities $ 18,898 Long-term operating lease liability Other liabilities 94,173 Total lease liabilities $ 113,071 Rent expense is recognized on a straight-line basis over the life of the lease. Rent expense consists of the following: Six months ended June 30, 2019 Operating lease costs $ 4,192 Short term lease cost 3,000 Total rent expense $ 7,192 Future minimum lease payments under non-cancellable leases were as follows: June 30, 2019 2019 - remaining 6 months $ 11,844 2020 24,161 2021 24,886 2022 25,633 2023 26,402 2024 and beyond 8,886 Total future minimum lease payments $ 121,812 Less: Interest 8,741 Total operating lease liabilities $ 113,071 Current operating lease liability $ 18,898 Long-term operating lease liability 94,173 Total operating lease liabilities $ 113,071

Notes Payable

Notes Payable	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Disclosure Text Block [Abstract]
Long-term Debt [Text Block]	Note 8 – Notes Payable Notes Payable In August 2016, INVO Bioscience converted a long-time vendor’s outstanding accounts payable balance of $131,722 into a Promissory Note with a three-year term that accrues interest at 5% per annum. The note provides for interest only payments on the first and second anniversaries of the note. The note is payable in full along with any outstanding accrued interest on August 9, 2019. The Company had the right to prepay the note at any time without a premium or penalty which it did in January 2019. The interest on this note for the three months ended June 30, 2019 and 2018 were $0 and $1,647, respectively. The interest on this note for the six months ended June 30, 2019 and 2018 were $489 and $3,293, respectively. The Note and all accrued interest of $9,823 was paid in full and as of June 30, 2019, the balance is $0. 2018 Convertible Notes Payable In April and May 2018, the Company issued convertible notes (the “2018 Convertible Notes”) payable to investors’ in the aggregate principal amount of $895,000. The 2018 Convertible Notes accrue interest at the rate of 9% per annum which is paid in stock. 2018 Convertible Notes with an aggregate principal amount of $550,000 are due on January 30, 2021, and 2018 Convertible Notes with an aggregate principal amount of $345,000 are due on March 31, 2021. The notes are convertible into shares of common stock at a price of $0.20 per share, provided, that if the Company completes a subsequent equity financing, the holders of the 2018 Convertible Notes can elect to convert the notes in shares of our common stock at a price equal to 75% of the price paid per share in such subsequent equity financing. During the fourth quarter of 2018, three note holders converted their notes with a value of $200,000 into 1,055,415 shares of common stock. During the six months ended June 30, 2019, a note holder converted principal and accrued interest of $50,000 and $3,723, respectively, into 268,615 shares of common stock. A second note holder converted 3 notes with total value of $185,000 into 925,000 shares of common stock; accrued interest of $16,550 had not been converted to stock as of June 30, 2019. The Company calculated a beneficial conversion feature of the 2018 Convertible Notes based on ASU 17-11 in the form of a discount of $895,000; $44,904 and $56,446 of this amount was amortized to interest expense during the three months ended June 30, 2019 and 2018, respectively, based on the three year term of the notes. In addition, $155,939 was also amortized for the notes that were converted during the first six months of 2019. During the six months ended June 30, 2019 and 2018 $26,445 and $14,343 of interest was expensed, respectively. The balance of these notes of $232,960 include the principal balance of $420,000, accrued interest of $61,042 net of the conversion discount of $248,082.	NOTE 6 CONVERTIBLE NOTES AND NOTES PAYABLE Convertible Notes - Bridge Notes During 2009, the Company issued senior secured convertible notes (“Bridge Notes”) payable to investors in the aggregate amount of $545,000. The Bridge Notes carry interest rates ranging between 10-12% and were due in full one year from the date of issuance and are past due. Both the Bridge Notes and the accrued interest thereon are convertible into Restricted Common Stock of the Company at a conversion price of $0.10 per share (the “Original Conversion Price”). If the Company were to issue any new shares of common stock within 24 months of the date of the Bridge Notes at a price below the Original Conversion Price, then the conversion price of the Bridge Notes would be adjusted to reflect the new lower price. In addition to the Bridge Notes, the Company issued warrants to purchase 5,750,000 shares of the Company’s Common Stock at a price of $0.20 per share as of the date of this filing. All the warrants have expired. The Company valued the conversion feature of the Bridge Notes and the warrants issued via the Black-Scholes valuation method. The total fair value calculated for the conversion feature was $1,473,710; $151,826 was allocated to discount on the Bridge Notes, and $1,341,884 was charged to operations. The total fair value calculated for the warrants was $1,719,666; $393,174 was allocated to discount on the Bridge Notes, and $1,326,492 was charged to operations. The aggregate discount on the Bridge Notes for the conversion feature and the warrants was $545,000, and the aggregate amount charged to operations was $2,668,371 which was recorded as a derivative liability on the Company’s consolidated balance sheet. From November 2009 through May 2015 $535,000 of the principal of the Bridge Notes were converted into shares of Restricted Common Stock. In March 2017, the Company converted the last Bridge Note in the amount of $10,000 and accrued interest into shares of common stock. The Company negotiated this conversion at a price lower than the conversion price stated in the original Bridge Note documents because the Bridge Note was past due. This conversion was treated as a restructure of debt on the Company’s financial statements for the six months ended June 30, 2017. $10,000 of the Bridge Notes and accrued interest were converted into 341,000 shares of restricted common stock resulting in a loss on debt settlement in the amount of $40,869. The principal balances of the Convertible Notes was $0 for both 2018 and 2017, respectively. The last note was converted in Q1 2017. The related interest for the twelve months ended December 31, 2018 and 2017 was $0. Notes Payable In August 2016, INVO Bioscience converted a long time vendor’s outstanding accounts payable balance of $131,722 into a three (3) year 5% notes payable. The note provides for interest only payments on the first and second anniversaries of the note. The note is payable in full along with any outstanding accrued interest on the third anniversary. The Company has the right to prepay the note at any time without a premium or penalty. The interest on this note for the years ended December 31, 2018 and 2017 was $6,586 and $9,586, respectively. 2018 Convertible Notes Payable In April and May 2018, the Company issued convertible notes (the “2018 Convertible Notes”) payable to investors in the aggregate principal amount of $895,000. The 2018 Convertible Notes accrue interest at the rate of 9% per annum which is paid in stock. 2018 Convertible Notes with an aggregate principal amount of $550,000 are due on January 30, 2021, and 2018 Convertible Notes with an aggregate principal amount of $345,000 are due on March 31, 2021. The notes are convertible into shares of common stock at a price of $0.20 per share, provided, that if the Company completes a subsequent equity financing, the holders of the 2018 Convertible Notes can elect to convert the notes in shares of our common stock at a price equal to 75% of the price paid per share in such subsequent equity financing. During the fourth quarter of 2018, three note holders converted their notes with a value of $200,000 into 1,055,415 shares of common stock. The Company calculated a beneficial conversion feature of the 2018 Convertible Notes based on ASU 17-11 in the form of a discount of $895,000; $366,126 of this amount was amortized to interest expense during the twelve months ended December 31, 2018, based on the three year term of the notes. In addition $53,564 of interest was expensed in the year ended December 31, 2018.

Notes Payable and Other Related

Notes Payable and Other Related Party Transactions	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 9 – Notes Payable and Other Related Party Transactions On September 18, 2008, the Company entered into a related party transaction with Dr. Claude Ranoux. Dr. Ranoux was then the President, Director and Chief Scientific Officer of the Company; as of the date of this filing he is a Director. Dr. Ranoux had loaned funds to the Company to sustain its operations since January 5, 2007 (inception). Dr. Ranoux’s total original cumulative investment as of December 31, 2008 was $96,462, as of December 31, 2017 and 2016 it was $21,888 (“the Principal Amount”) in INVO Bioscience. On March 26, 2009, the Company and Dr. Ranoux agreed to re-write the agreement to a non-convertible note payable bearing interest at 5% per annum, the term of the note had been extended, and has been extended a couple of additional times, the current repayment date was October 31, 2018. The Company and Dr. Ranoux could jointly decide to repay the loan earlier without prepayment penalties. During the twelve months ended December 31, 2018 the outstanding balance of $21,888 was paid in full including all interest due. On March 5, 2009, the Company entered into a related party transaction with Kathleen Karloff, the Chief Executive Officer and a Director of the Company. Ms. Karloff provided a short-term loan in the amount of $75,000 bearing interest at 5% per annum to the Company to fund operations. In May 2009, Ms. Karloff loaned to the Company an additional $13,000, making her total cumulative loan $88,000 as of December 31, 2011. This note was due on September 15, 2009, which has since been extended a few times to its current date of October 31, 2018. During the twelve months ended December 31, 2014, Ms. Karloff loaned the Company an additional $66,000 at an interest rate of 0% by entering into a note payable agreement in satisfaction of expenses incurred by her for amounts previously advanced to the Company. This note currently has the same expiration date as the others which is October 31, 2018. During the twelve months ended December 31, 2018 $91,257 was paid against the principal of the loan, in 2017, $0 was repaid on the principal of the loan. The principal balances of the loan were $62,743 and $154,000 as of December 31, 2018 and 2017, respectively. The related interest for the twelve months ended December 31, 2018 and 2017 was $15,278 and $4,400 respectively. During the six months ended June 30, 2019, the Company paid the remaining balance due Ms. Karloff in the amount of $62,743 along with $44,000 of accrued interest. In December 2009, James Bowdring, the brother of Director Robert Bowdring invested $100,000 acquiring 666,667 shares of restricted common stock. In April 2011, the Company issued a new short-term convertible note (“Q211 Note”) payable to James Bowdring in the amount of $50,000. The Note carries a 10% interest rate. The note has a current balance of $25,000. The Q211 Note is convertible into Common Stock of the Company at a conversion price of $0.03 per share, subject to adjustments. During the three and six months ended June 30, 2019, the Company accrued interest in the amount of $623 and $1,239 on the Q211 Note, respectively. In November 2011, the Company issued a new convertible note (“Q411 Note”) payable to James Bowdring in the amount of $10,000. The Q411 Note carries a 10% interest rate. The Q411 Note is convertible into Common Stock of the Company at a conversion price of $0.01 per share, subject to adjustments. During the three months ended June 30, 2019 and 2018, the Company accrued interest in the amount of $249 and $249 on the Q411 Note, respectively. In addition, $496 and $496 of interest was accrued in the six months ended June 30, 2019 and 2018, respectively. In May 2018, James Bowdring and his children participated in the “2018 Convertible Notes” offerings in the aggregate principal amount of $40,000. The 2018 Convertible Notes accrue interest at the rate of 9% per annum which is paid in stock. These Notes are due on March 31, 2021. The notes are convertible into shares of common stock at a price of $0.20 per share, provided, that if the Company completes a subsequent equity financing, the holders of the 2018 Convertible Notes can elect to convert the notes in shares of our common stock at a price equal to 75% of the price paid per share in such subsequent equity financing. During the three months ended June 30, 2019 and 2018, the Company accrued interest in the amount of $897 and $562 on the 2018 Convertible Notes, respectively. In addition, $1,785 and $562 of interest was accrued in the six months ended June 30, 2019 and 2018, respectively. The Company had been renting its corporate office from Forty Four Realty Trust which is owned by James Bowdring, the brother of Director & Former Acting Chief Financial Officer, Robert Bowdring since November 2012 in a month to month rental arrangement. The Company believes the rent of $600 per month was less than the fair market real estate rental rate for comparable leases. The lease terminated in May 2019, when the company relocated to a new facility. In addition, the Company had purchased stationary supplies and marketing items at discounted rates from Superior Printing & Promotions which is also owned by James Bowdring and is in the same building as our former corporate office. INVO Bioscience spent $5,256 and $234 with Superior during the three months ended June 30, 2019 and 2018, respectively. In addition, INVO Bioscience spent $6,034 and $234 in the six months ended June 30, 2019 and 2018, respectively. Principal balances of the Related Party loans were as follows: June 30, 2019 December 31, 2018 James Bowdring Family - 2011 Notes 35,000 35,000 James Bowdring Family – 2018 Convertible Notes 44,161 40,000 Kathleen Karloff Note - 62,743 Less discount (24,089 ) (30,913 ) Total, net of discount $ 55,072 $ 106,830 Interest expense on the Related Party loans was $1,770 and $2,247 for the three months ended June 30, 2019 and 2018, respectively. In addition, $3,521 and $5,039 of interest expense was recorded in the six months ended June 30, 2019 and 2018, respectively. Accounts payable and accrued liabilities balances include expenses reports for Ms. Karloff and Mr. Bowdring for expenses they paid for personally related to travel or normal business expenses. June 30, December 31, 2019 2018 Accounts payable and accrued liabilities $ 3,702 $ 1,700	NOTE 7 OTHER RELATED PARTY TRANSACTIONS On September 18, 2008, the Company entered into a related party transaction with Dr. Claude Ranoux. Dr. Ranoux was then the President, Director and Chief Scientific Officer of the Company; as of the date of this filing he is a Director. Dr. Ranoux had loaned funds to the Company to sustain its operations since January 5, 2007 (inception). Dr. Ranoux’s total original cumulative investment as of December 31, 2008 was $96,462, as of December 31, 2017 and 2016 it is $21,888 (“the Principal Amount”) in INVO Bioscience. On March 26, 2009, the Company and Dr. Ranoux agreed to re-write the agreement to a non-convertible note payable bearing interest at 5% per annum, the term of the note had been extended, and has been extended a couple of additional times, the current repayment date is October 31, 2018. The Company and Dr. Ranoux can jointly decide to repay the loan earlier without prepayment penalties. During the twelve months ended December 31, 2018 the outstanding balance of $21,888 was paid in full including all interest due, in 2017, $0 was repaid on the principal of the loan. On March 5, 2009, the Company entered into a related party transaction with Kathleen Karloff, the Chief Executive Officer and a Director of the Company. Ms. Karloff provided a short-term loan in the amount of $75,000 bearing interest at 5% per annum to the Company to fund operations. In May 2009, Ms. Karloff loaned to the Company an additional $13,000, making her total cumulative loan $88,000 as of December 31, 2011. This note was due on September 15, 2009, which has since been extended a few times to its current date of October 31, 2018. During the twelve months ended December 31, 2014, Ms. Karloff loaned the Company an additional $66,000 at an interest rate of 0% by entering into a note payable agreement in satisfaction of expenses incurred by her for amounts previously advanced to the Company. This note currently has the same expiration date as the others which is October 31, 2018. During the twelve months ended December 31, 2018 $91,257 was paid against the principal of the loan, in 2017, $0 was repaid on the principal of the loan. The principal balances of the loan was $62,743 and $154,000 as of December 31 2018 and 2017 respectively. The related interest for the twelve months ended December 31, 2018 and 2017 was $15,278 and $4,400 respectively. In December 2009, James Bowdring, the brother of Director Robert Bowdring invested $100,000 acquiring 666,667 shares of restricted common stock. In April 2011, the Company issued a new short term convertible note (“Q211 Note”) payable to James Bowdring in the amount of $50,000. The Note carries a 10% interest rate. The note has a current balance of $25,000. The Q211 Note is convertible into Common Stock of the Company at a conversion price of $0.03 per share, subject to adjustments. In November 2011, the Company issued a new convertible note (“Q411 Note”) payable to James Bowdring in the amount of $10,000. The Q411 Note carries a 10% interest rate. The Q411 Note is convertible into Common Stock of the Company at a conversion price of $0.01 per share, subject to adjustments. In May 2018, James Bowdring and his children participated in the “2018 Convertible Notes” offerings in the aggregate principal amount of $40,000. The 2018 Convertible Notes accrue interest at the rate of 9% per annum which is paid in stock. These Notes are due on March 31, 2021. The notes are convertible into shares of common stock at a price of $0.20 per share, provided, that if the Company completes a subsequent equity financing, the holders of the 2018 Convertible Notes can elect to convert the notes in shares of our common stock at a price equal to 75% of the price paid per share in such subsequent equity financing. The Company has been renting its corporate office from Forty Four Realty Trust which is owned by James Bowdring, the brother of Director, Robert Bowdring since November 2012. It is a month to month rental arrangement for less than the going fair market real estate rental rate. The rent expense paid for the twelve months ended December 31, 2018 and 2017 was $5,600 and $4,400 respectively. In addition the Company purchases stationary supplies and marketing items at discounted rates from Superior Printing & Promotions which is also owned by James Bowdring and is in the same building as our corporate office. INVO Bioscience spent $2,130 and $4,100 with Superior during 2018 and 2017, respectively. Principal balances of the Related Party loans were as follows: December 31, 2018 December 31, 2017 Claude Ranoux Note $ - $ 21,888 James Bowdring Family - 2011 Notes 35,000 35,000 James Bowdring Family – 2018 Convertible Notes 40,000 - Kathleen Karloff Note 62,743 154,000 Less discount (30,913 ) - Total, net of discount $ 106,830 $ 210,888 Interest expense on the Related Party loans was $21,976 and $11,543 for the years ended December 31, 2018 and 2017, respectively. Accounts payable and accrued liabilities balances include expenses reports for Ms. Karloff, and Mr. Bowdring for expenses they paid for personally related to travel or normal business expenses and are represented in the following table: December 31, 2018 2017 Accounts payable and accrued liabilities $ 1,700 $ 38,000 During the nine months ended September 30, 2018, the Company sold 150,000 shares of common stock at a price of $0.20 per share for proceeds of $30,000 to Charles Mulrey and family, the brother-in-law of Robert J. Bowdring, Director & Acting Chief Financial Officer as part of the recent financing. During the second quarter of 2018, INVO Bioscience settled a commitment it had with one of its Directors, Dr. Kevin Doody for the services he and his team performed prior to and following INVOcell’s FDA clearance related to clinical guidance and support. Dr. Doody and his team performed clinical studies and provided papers, lectures and discussions with regulatory bodies and key opinion leaders in the industry. The Company believes without Dr. Doody’s services and support during his tenure the Company would not be where it is today. The Company issued Dr. Doody 3 million shares of our common stock with a fair value of $1,530,000.

Stockholders' Equity

Stockholders' Equity	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 10 – Stockholders’ Equity Six Months Ended June 30, 2019 In January 2019, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 60,000 shares of common stock with a fair value of $26,600 to service providers. In February 2019, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 268,615 shares of common stock for conversion of notes payable and accrued interest in the amount of $53,723. In April 2019, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 800,000 shares of common stock for conversion of notes payable in the amount of $160,000. In May 2019, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 125,000 shares of common stock for conversion of notes payable in the amount of $25,000. Six Months Ended June 30, 2018 In January and March 2018, pursuant to Section 4(a)(2) of the Securities Act, the Company sold 260,000 shares of common stock to accredited investors in a private placement for cash of $47,000. In January 2018, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 1,200,000 shares of common stock with a fair value of $138,000 to management and board members. In January and March 2018, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 352,326 shares of common stock with a fair value of $43,664 to service providers. In April and May 2018, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 340,000 shares of common stock with a fair value of $174,800 to service providers. In May 2018, pursuant to Section 4(a)(2) of the Securities Act, the Company sold 150,000 shares of common stock to accredited investors who are family members of Robert J Bowdring, a Board Member in a private placement for cash of $30,000 In May 2018, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 3,020,000 shares of common stock with a fair value of $1,540,000 to a board member, Dr. Kevin Doody for services provided to the Company.	NOTE 8 STOCKHOLDERS’ EQUITY Twelve Months Ended December 31, 2018 In January and March 2018, pursuant to Section 4(a)(2) of the Securities Act, the Company sold 260,000 shares of common stock to accredited investors in a private placement for cash of $47,000. In January 2018, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 1,200,000 shares of common stock with a fair value of $138,000 to management and board members. In January and March 2018, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 352,326 shares of common stock with a fair value of $43,664 to service providers. In April and May 2018, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 340,000 shares of common stock with a fair value of $174,800 to service providers. In May 2018, pursuant to Section 4(a)(2) of the Securities Act, the Company sold 150,000 shares of common stock to accredited investors who are family members of Robert J Bowdring, a Board Member in a private placement for cash of $30,000. In May 2018, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 3,020,000 shares of common stock with a fair value of $1,540,000 to a board member, Dr. Kevin Doody for services previously provided to the Company. In October 2018, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 4,895,076 shares of common stock with a fair value of $1,914,831 to employees and service providers. In November 2018, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 262,080 shares of common stock for conversion of notes payable and accrued interest in the amount of $52,416. In December 2018, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 793,335 shares of common stock for conversion of notes payable and accrued interest in the amount of $158,667. In December 2018, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 887,306 shares of common stock with a fair value of $349,602 to employees and service providers. Twelve Months Ended December 31, 2017 In March 2017, pursuant to Section 4(2) of the Securities Act, the Company issued 196,000 shares of restricted common stock with a fair value of $59,242 to service providers. In March 2017, pursuant to Section 4(2) of the Securities Act, the Company negotiated the conversion of $10,000 of past due Bridge Notes and accrued interest into 341,000 shares of restricted common stock resulting in a loss on debt settlement in the amount of $40,869. In April 2017, pursuant to Section 4(2) of the Securities Act, the Company issued 51,750 shares of restricted common stock with a fair value of $17,201 to service providers. In June 2017, pursuant to Section 4(2) of the Securities Act, the Company issued 99,412 shares of restricted common stock with a fair value of $30,898 to service providers. In September 2017, pursuant to Section 4(2) of the Securities Act, the Company issued 133,960 shares of restricted common stock with a fair value of $28,576 to service providers. In September 2017, pursuant to Section 4(2) of the Securities Act, the Company issued 262,500 shares of restricted common stock for cash proceeds of $44,625. In November 2017, pursuant to Section 4(2) of the Securities Act, the Company issued 395,550 shares of restricted common stock with a fair value of $79,215 to service providers. In November 2017, pursuant to Section 4(2) of the Securities Act, the Company issued 55,556 shares of restricted common stock for cash proceeds of $10,000.

Stock Options and Warrants

Stock Options and Warrants	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Disclosure Text Block Supplement [Abstract]
Shareholders' Equity and Share-based Payments [Text Block]	Note 11 – Stock Options and Warrants As of June 30, 2019 and December 31, 2018, the Company does not have any outstanding or committed and unissued stock options or warrants.	NOTE 9 STOCK OPTIONS AND WARRANTS Stock Options As of December 31, 2018 and 2017, the Company does not have any outstanding or committed and unissued stock options. Warrants As of December 31, 2018 and 2017, the Company does not have any outstanding or committed and unissued warrants.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 12 – Commitments and Contingencies A) Litigation In April 2019 the Company took steps to move this litigation forward. INVO Bioscience has been waiting for the plaintiffs to file the proper court documentation since October 2016. Through their attorney INVO Bioscience issued an appeal with a motion to dismiss the plaintiffs’ appeal in the Superior Court of Suffolk County in Massachusetts. In May 2019 the plaintiffs filed the required paperwork, our attorney quickly filed a reply brief to have the notice of appeal struck with the court attacking their claims as it has done in the past. The Court responded by setting a hearing date in September 2019 to review our motion to dismiss. The Company and its attorney feels this is a positive step in getting this situation resolved. There had been no change in the status of the litigation INVO Bioscience, Inc., and two of its directors have been involved in since 2010, defending litigation brought by investors in an alleged predecessor of INVO Bioscience. On March 24, 2010, INVO Bioscience, Inc. and its corporate affiliate, Bio X Cell, Inc., Claude Ranoux, and Kathleen Karloff were served an Amended Complaint, the original of which was filed on December 31, 2009 at the Suffolk Superior Court Business Litigation Session by two terminated employees of Medelle Corporation (also named as a co-defendant but no longer active), who are also attorneys, and a former investor in and creditor of Medelle. These plaintiffs allege various claims of wrongdoing relating to the sale of assets of Medelle to Dr. Ranoux. Plaintiffs claim that Dr. Ranoux, Ms. Karloff, and Medelle (and therefore INVO Bioscience as an alleged successor corporation) violated alleged duties owed to plaintiffs in connection with the sale. Separate claims were also alleged against INVO Bioscience. Dr. Ranoux, Ms. Karloff, and INVO Bioscience have challenged these allegations, which they believe are baseless. The transfer of the assets of Medelle was professionally handled by an independent third party, after approval by the Medelle Board of Directors, representing a majority of its shareholders. Medelle’s Board voted to proceed with an assignment for the benefit of creditors (AFBC) and gave complete authority to the President & CEO at that time (neither Dr. Ranoux nor Ms. Karloff) to work with the third-party assignee and to get the best possible price for those assets. The third party was responsible for notifying all the appropriate parties and for filing notices in various professional publications and newspapers of Medelle’s intention to sell its assets. The third party also contacted numerous large medical device and bio-pharma companies to learn if they would be interested in acquiring the assets. After a private sale was deemed unlikely, the assignee of the assets elected to proceed with a sealed-bid auction of the assets. On the day of the auction, Dr. Ranoux submitted the only bid and was awarded the assets, upon full payment. During 2010, Dr. Ranoux, Ms. Karloff, and INVO Bioscience filed Motions to Dismiss as to all claims, pursuant to M.R.Civ. P. 12(b)(6). In a written Decision rendered on November 12, 2010, the judge dismissed all claims against INVO, Bio X Cell, and Ms. Karloff, and also dismissed the claims against Dr. Ranoux alleging civil conspiracy and breach of M.G.L. c. 93A. The judge denied Dr. Ranoux’s motion to dismiss the remaining breach of fiduciary duty and fraud claims. The plaintiffs allege in their Amended Complaint that Dr. Ranoux committed fraud by failing to inform them of the details of the Medelle auction. The claims against Dr. Ranoux that survived the November 2010 dismissal order were submitted to binding arbitration. On February 15, 2013, the mutually-agreed arbitrator ruled in favor of Dr. Ranoux. The award held that Dr. Ranoux did not withhold information about the auction of Medelle’s assets and expressed doubt that the plaintiffs would have invested the resources necessary to make a beneficial use of the assets. The arbitrator’s award then was confirmed by the Superior Court on August 21, 2013. The Superior Court’s confirmation of the award was affirmed on appeal on October 20, 2013 by the Massachusetts Appeals Court. The Massachusetts Supreme Judicial Court then denied further appellate review. On October 18, 2016, following motions and argument, the Superior Court issued a memorandum of decision and order denying plaintiffs’ motion for entry of default judgment and assessment of damages against Medelle and allowed the motion of INVO Bioscience, Bio X Cell, and Ms. Karloff for entry of final judgment of dismissal. The foregoing order was converted to a final judgment dismissing all claims against all defendants and entered on the docket on October 27, 2016. On November 28, 2016, plaintiffs filed an amended notice of appeal from the Superior Court’s decision of October 17, 2016 and the subsequent judgment entered on October 27, 2016. The appeal further challenges the order of dismissal from November, 2010. Plaintiffs did not appeal from the dismissal of the claims against Ms. Karloff, so the judgment in her favor is now final, leaving claims against INVO Bioscience, Bio X Cell, Medelle, and Dr. Ranoux. INVO Bioscience and Bio X Cell intend a vigorous opposition to the current appeal, consistent with their previous positions that no breach of duty occurred in the sale of Medelle’s assets. It is assumed that Dr. Ranoux will oppose the appeal as well. Outside of the above-mentioned litigation, neither INVO Bioscience nor Bio X Cell, our wholly-owned subsidiary, either directly or indirectly, are involved in any lawsuit outside the ordinary course of business, the disposition of which would have a material effect upon either our results of operation, financial position, or cash flows. B) Employee Agreements The Company is in the process of updating employment agreements for its current officers, executives and employees of the Company. C) Consulting Agreements The Company has entered into a consulting agreement with Shine Management, Inc. through which it is receiving outsourced accounting and the support of its acting CFO, Debra Hoopes. Debra is the CFO and Chief Administrative Officer of Shine Management, Inc. and Management Services Company in Charlottesville, VA. The Company has a verbal agreement beginning in March, 2013 with its former CFO, Robert Bowdring, who is currently a Director, to assist where necessary in the financial and administrative areas of the Company for compensation to be equivalent to the others working in the organization.	NOTE 11 COMMITMENTS AND CONTINGENCIES A) Operating Leases In November 2012, INVO Bioscience entered into a below market, month to month rental agreement with Forty Four Realty Trust with for the space it requires. Forty Four Realty Trust is owned by investor James Bowdring, the brother of Director Robert Bowdring. B) Litigation INVO Bioscience, Inc., and two of its directors have been, since 2010, defending litigation brought by investors in an alleged predecessor of INVO Bioscience. On March 24, 2010, INVO Bioscience, Inc. and its corporate affiliate, Bio X Cell, Inc., Claude Ranoux, and Kathleen Karloff were served an Amended Complaint, the original of which was filed on December 31, 2009 at the Suffolk Superior Court Business Litigation Session by two terminated employees of Medelle Corporation (also named as a co-defendant but no longer active), who are also attorneys, and a former investor in and creditor of Medelle. These plaintiffs allege various claims of wrongdoing relating to the sale of assets of Medelle to Dr. Ranoux. Plaintiffs claim that Dr. Ranoux, Ms. Karloff, and Medelle (and therefore INVO Bioscience as an alleged successor corporation) violated alleged duties owed to plaintiffs in connection with the sale. Separate claims were also alleged against INVO Bioscience. Dr. Ranoux, Ms. Karloff, and INVO Bioscience have challenged these allegations, which they believe are baseless. The transfer of the assets of Medelle was professionally handled by an independent third party, after approval by the Medelle Board of Directors, representing a majority of its shareholders. Medelle’s Board voted to proceed with an assignment for the benefit of creditors (AFBC) and gave complete authority to the President & CEO at that time (neither Dr. Ranoux nor Ms. Karloff) to work with the third-party assignee and to get the best possible price for those assets. The third party was responsible for notifying all the appropriate parties and for filing notices in various professional publications and newspapers of Medelle’s intention to sell its assets. The third party also contacted numerous large medical device and bio-pharma companies to learn if they would be interested in acquiring the assets. After a private sale was deemed unlikely, the assignee of the assets elected to proceed with a sealed-bid auction of the assets. On the day of the auction, Dr. Ranoux submitted the only bid and was awarded the assets, upon full payment. During 2010, Dr. Ranoux, Ms. Karloff, and INVO Bioscience filed Motions to Dismiss as to all claims, pursuant to M.R.Civ. P. 12(b)(6). In a written Decision rendered on November 12, 2010, the judge dismissed all claims against INVO, Bio X Cell, and Ms. Karloff, and also dismissed the claims against Dr. Ranoux alleging civil conspiracy and breach of M.G.L. c. 93A. The judge denied Dr. Ranoux’s motion to dismiss the remaining breach of fiduciary duty and fraud claims. The plaintiffs allege in their Amended Complaint that Dr. Ranoux committed fraud by failing to inform them of the details of the Medelle auction. The claims against Dr. Ranoux that survived the November 2010 dismissal order were submitted to binding arbitration. On February 15, 2013, the mutually-agreed arbitrator ruled in favor of Dr. Ranoux. The award held that Dr. Ranoux did not withhold information about the auction of Medelle’s assets and expressed doubt that the plaintiffs would have invested the resources necessary to make a beneficial use of the assets. The arbitrator’s award then was confirmed by the Superior Court on August 21, 2013. The Superior Court’s confirmation of the award was affirmed on appeal on October 20, 2013 by the Massachusetts Appeals Court. The Massachusetts Supreme Judicial Court then denied further appellate review. On October 18, 2016, following motions and argument, the Superior Court issued a memorandum of decision and order denying plaintiffs’ motion for entry of default judgment and assessment of damages against Medelle and allowed the motion of INVO Bioscience, Bio X Cell, and Ms. Karloff for entry of final judgment of dismissal. The foregoing order was converted to a final judgment dismissing all claims against all defendants and entered on the docket on October 27, 2016. On November 28, 2016, plaintiffs filed an amended notice of appeal from the Superior Court’s decision of October 17, 2016 and the subsequent judgment entered on October 27, 2016. The appeal further challenges the order of dismissal from November, 2010. Plaintiffs did not appeal from the dismissal of the claims against Ms. Karloff, so the judgment in her favor is now final, leaving claims against INVO Bioscience, Bio X Cell, Medelle, and Dr. Ranoux. INVO Bioscience and Bio X Cell intend a vigorous opposition to the current appeal, consistent with their previous positions that no breach of duty occurred in the sale of Medelle’s assets. It is assumed that Dr. Ranoux will oppose the appeal as well. Outside of the above-mentioned litigation, neither INVO Bioscience nor Bio X Cell, our wholly-owned subsidiary, either directly or indirectly, are involved in any lawsuit outside the ordinary course of business, the disposition of which would have a material effect upon either our results of operation, financial position, or cash flows. C) Employee Agreements The Company had employment agreements for officers, executives and employees of the Company in place but they have expired. The Company in the in the process of drafting new agreements for all of its key personnel. D) Consulting Agreements The Company has a verbal agreement beginning in March, 2013 with its former CFO, Robert Bowdring, who is currently a Director, to assist where necessary in the financial and administrative areas of the Company for compensation to be equivalent to the others working in the organization.

Contracts with Customers

Contracts with Customers	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer [Text Block]	Note 13 – Contracts with Customers We have adopted ASC 606, Revenue from Contracts with Customers . Revenue Recognition Revenues for products, including: INVOcell ® TM In January 2019, we announced a U.S. license and distribution agreement with Ferring International Center S.A. (“Ferring”) and as a result took a significant step to strengthen the Company that we believe will allow us to implement our overall business plan. We believe that this strategic partnership with a strong reproductive organization such as Ferring Pharmaceuticals will provide us with the necessary sales and marketing resources within the United States to expand the market and help reach all of those couples not receiving reproductive treatments today. The agreement calls for the issuance of an initial upfront payment of $5,000,000 which we received upon the signing of the agreement and then subsequent licensing fee payment of $3,000,000 that will provide us with a source of non-dilutive financing to execute our plan. Under the terms of the agreement we can pursue developing international markets and as well as partnering and opening INVO-only reproductive centers within the U.S. market. We believe this major milestone and agreement is a critical step that allows the Company to implement its mission of expanding access to care in the fertility marketplace. The initial upfront payment of $5,000,000 which we received upon the signing of the agreement is being recognized to income over the 7 year term. Under the terms of the Distribution Agreement, Ferring completed its obligation to make an initial payment to the Company of $5,000,000 upon completion of the required closing conditions, including executed agreements from all current manufacturers of the Licensed Product that upon a material supply default by the Company, Ferring can assume a direct purchase relationship with such manufacturers. Ferring is obligated to make a second payment to the Company of $3,000,000 provided that the Company is successful in obtaining a five (5) day label enhancement from the FDA for the current incubation period for the Licensed Product at least three (3) years prior to the expiration of the term of the license for the Licensed Product and provided further that Ferring has not previously exercised its right to terminate the Distribution Agreement for convenience. In addition, the Company entered into a separate Distribution Agreement. The Distribution Agreement has an initial term expiring on December 31, 2025 and at the end of the initial term it may be terminated by the Company if Ferring fails to generate specified minimum revenues to the Company from the sale of the Licensed Product during the final two years of the initial term. The Ferring license was deemed to be a functional license that provide customers with a “right to access” to our intellectual property during the subscription period and, accordingly, revenue is recognized over a period of time, which is generally the subscription period. During the three months and six months ended June 30, 2019, the Company recognized $178,571 and $357,143, respectively, related to the Ferring license agreement. As of June 30, 2019 and December 31, 2018, the Company had deferred revenues of $4,655,832 and $18,895, respectively. Sources of Revenue We have identified the following revenues disaggregated by revenue source: Domestic Product revenue Domestic Licensing fee For the six months ended June 30, 2019 and 2018 the source of revenue was derived from: June 30, 2019 June 30, 2018 Domestic Product revenue $ 490,927 $ 214,350 Domestic licensing fee 357,143 - Total revenue $ 848,070 $ 214,350 Contract Balances We incur agreement obligations on general customer purchase orders and e-mails that have been accepted but unfulfilled. Due to the short duration of time between order acceptance and delivery of the related product, we have determined that the balance related to these obligations is generally immaterial at any point in time. We monitor the value of orders accepted but unfulfilled at the close of each reporting period to determine if disclosure is appropriate. Warranty Our general product warranties do not extend beyond an assurance that the product delivered will be consistent with stated specifications and do not include separate performance obligations. Commissions and Contract Costs We do not use or offer sales commissions of any type at this time. We generally do not incur incremental charges associated with securing agreements with customers which would require capitalization and recovery over the life of the agreement. Practical Expedients Our payment terms for sales direct to customers and distributors are substantially less than the one-year collection period that falls within the practical expedient in determination of whether a significant financing component exists. Shipping and Handling Charges Fees charged to customers for shipping and handling of products are included as an offset to the costs for shipping and handling of products included as a component of cost of products. Taxes Collected from Customers As our products are used in another service and are exempt, to this point we have not collected taxes. If we were to collect taxes, they would be on the value of transaction revenue and would be excluded from product revenues and cost of sales and would be accrued in current liabilities until remitted to governmental authorities. Effective Date and Transition Disclosures Adoption of the new standards related to revenue recognition did not have a material impact on our consolidated financial statements, and is not expected to have a material impact in future periods.	NOTE 12 CONTRACTS WITH CUSTOMERS We have adopted ASC 606, Revenue from Contracts with Customers . Revenue Recognition We routinely enter into agreements with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms and in most cases prices for the products that we offer. However, these agreements do not obligate us to provide goods to the customer and there is no consideration promised to us at the onset of these arrangements. For customers without separate agreements, we have a standard list price established by geography and by currency for all products and our invoices contain standard terms and conditions that are applicable to those customers where a separate agreement is not controlling. Our performance obligations are established when a customer submits a purchase order or e-mail notification (in writing, electronically or verbally) for goods, and we accept the order. We identify performance obligations as the delivery of the requested product(s) in appropriate quantities and to the location specified in the customer’s e-mail/or purchase order. We generally recognize revenue upon the satisfaction of these criteria when control of the product has been transferred to the customer at which time we have an unconditional right to receive payment. Our prices are fixed and are not affected by contingent events that could impact the transaction price. We do not offer price concessions and do not accept payment that is less than the price stated when we accept the purchase order, except in rare credit related circumstances. We do not have any material performance obligations where we are acting as an agent for another entity. Revenues for products, including: INVOcell ® TM Sources of Revenue We have identified the following revenues disaggregated by revenue source: 1. Domestic Physicians – direct sales of products. 2. Domestic Distributors – direct sales of products 3. International Distributors – direct sales of products. For the year ended December 31, 2018 the primary source of our revenue was from Domestic Physicians, the Company had $61,000 in shipments to its Domestic Distributor and 2017 the source of revenue was only from Domestic Physicians. Contract Balances We incur agreement obligations on general customer purchase orders and e-mails that have been accepted but unfulfilled. Due to the short duration of time between order acceptance and delivery of the related product, we have determined that the balance related to these obligations is generally immaterial at any point in time. We monitor the value of orders accepted but unfulfilled at the close of each reporting period to determine if disclosure is appropriate. Warranty Our general product warranties do not extend beyond an assurance that the product delivered will be consistent with stated specifications and do not include separate performance obligations. Significant Judgments in the Application of the Guidance in ASC 606 There are no significant judgments associated with the satisfaction of our performance obligations. We generally satisfy performance obligations upon delivery of the product to the customer. This is consistent with the time in which the customer obtains control of the products. Therefore the value of unsatisfied performance obligations at the end of any reporting period is generally immaterial. We consider variable consideration in establishing the transaction price. Forms of variable consideration applicable to our arrangements include sales returns, rebates, volume based bonuses, and prompt pay discounts. We use historical information along with an analysis of the expected value to properly calculate and to consider the need to constrain estimates of variable consideration. Such amounts are included as a reduction to revenue from the sale of products in the periods in which the related revenue is recognized and adjusted in future periods as necessary. Commissions and Contract Costs We do not use or offer sales commissions of any type at this time. We generally do not incur incremental charges associated with securing agreements with customers which would require capitalization and recovery over the life of the agreement. Practical Expedients Our payment terms for sales direct to customers and distributors are substantially less than the one year collection period that falls within the practical expedient in determination of whether a significant financing component exists. Shipping and Handling Charges Fees charged to customers for shipping and handling of products are included as an offset to the costs for shipping and handling of products included as a component of cost of products. Taxes Collected from Customers As our products are used in another service and are exempt, to this point we have not collected taxes. If we were to collect taxes they would be on the value of transaction revenue and would be excluded from product revenues and cost of sales and would be accrued in current liabilities until remitted to governmental authorities. Effective Date and Transition Disclosures Adoption of the new standards related to revenue recognition did not have a material impact on our consolidated financial statements, and is not expected to have a material impact in future periods.

Subsequent Events

Subsequent Events	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 14 – Subsequent Events On August 7, 2019, the Company sent James Bowdring, a related party, a check in the amount of $65,197 as full and final payment under those certain promissory notes dated April 8, 2011 and November 9, 2011. On August 8, 2019, Mr. Bowdring’s legal counsel returned the check. A basis for returning the check was a claim that the interest due under the Notes called for compounded interest and not per annum interest. In addition, the letter rejecting the tender of the payment in full check alleged Mr. Bowdring was considering a future intention to convert his Promissory Notes into shares of the Company’s common stock. Mr. Bowdring, through his counsel, indicated that such future intention to convert the Notes to common stock were contingent upon Mr. Bowdring addressing certain personal issues which were not disclosed by his counsel in the correspondence returning the checks. The Company does not believe that Mr. Bowdring has the right to seek conversion of the Notes once payment for the Notes has been tendered. In order to resolve the issue of the Company’s tender of payment in full versus Mr. Bowdring’s assertion that he can reject tender and seek conversion, the Company has filed an action in the Suffolk Superior Court in Boston seeking Declaratory Judgment and Judgment for Breach of Contract. The 10% Senior Secured Convertible Promissory Notes were issued on April 8, 2011 and November 9, 2011, with maturity dates thirty days subsequent to the dates of issuance. Interest was calculated at 10% per annum, compounded based on a 360-day year. Investors had the option to convert any unpaid principal and accrued interest into shares of Company’s common stock original conversion prices of $.03 and $.01, respectively, subject to adjustments upon the Company’s issuances of stock at prices less than the original conversion prices during the 24-months after issuance of each note (i.e. currently $0.0065).	NOTE 13 SUBSEQUENT EVENTS On January 14, 2019, the Company consummated the transactions contemplated by its previously reported Distribution Agreement with Ferring International Center S.A. (“Ferring”), dated November 12, 2018. At the closing, the Company received its initial $5,000,000 license fee. Pursuant to the Distribution Agreement, among other things, the Company granted to Ferring an exclusive license in the United States with rights to sublicense under patents related to the Company’s proprietary intravaginal culture device known as INVOcell™, together with the retention device and any other applicable accessories to market, promote, distribute and sell the Licensed Product with respect to all therapeutic, prophylactic and diagnostic uses of medical devices or pharmaceutical products involving reproductive technology (including infertility treatment) in humans. Ferring is responsible, at its own cost, for all commercialization activities for the Licensed Product in humans in the U.S. The Company does retain a limited exception to the exclusive license granted to Ferring allowing the Company, subject to certain restrictions, to establish up to five clinics that will commercialize INVO cycles in the U.S.. The Company retains all commercialization rights for the Licensed Product outside of the United States. In January 2019 we hired Mr. Michael Campbell as COO and VP of Business Development. Mr. Campbell has been on our Board of Directors for the past sixteen months. He has over 20 years in the infertility market most recently with Cooper Surgical as the VP of the IVF America division and previously in the position of VP of the international IVF market. In January 2019, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 60,000 shares of restricted common stock with a fair value of $26,600 to service providers for services performed. In February 2019, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 268,615 shares of restricted common stock with a fair value of $53,168 in connection with the conversion of a note payable and accrued interest. In March 2019 the Company decided to change its stock transfer agent from Island Stock Transfer Company to Transfer Online, Inc. https://www.transferonline.com/ as Island is no longer able to meet the needs of INVO Bioscience.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (A) General INVO Bioscience, Inc. (“the Company”) offers novel solutions in assisted reproductive technologies while expanding geographic and affordable access to the global reproductive health care community. Our primary focus is the manufacture and sale of the INVOcell device and the INVO technology to assist infertile couples in having a baby. We designed our INVOcell device and our INVO procedure to provide an alternative infertility treatment for the patient and the clinician. The INVO procedure is less expensive and simpler to perform than other comparable infertility treatments. The simplicity of the INVO procedure relates to the ability to potentially perform the INVO procedure in a physician’s practice rather than in a specialized facility at a much lower cost overall than current infertility treatments. We believe that the INVO procedure will make infertility treatment more readily available throughout the world. The INVO procedure is less costly than conventional IVF. The INVOcell device and INVO procedure facilitates conception and embryo development inside the woman’s body, rather than in a dish in a laboratory, which is an attractive feature for many couples. Through December 31, 2018, we have generated minimal revenues, have incurred significant expenses and have sustained losses. Consequently, our operations are subject to all the risks inherent in the establishment of a new business enterprise. On November 3, 2015, the Company issued a press release reporting the U.S. Food and Drug Administration (“FDA”) has granted the Company’s de novo request for the INVOcell to allow the marketing, sale and use in the United States. On November 12, 2018, the Company entered into a Distribution Agreement with Ferring pursuant to which, among other things, the Company granted to Ferring an exclusive license in the United States with rights to sublicense under patents related to the Company’s proprietary intravaginal culture device known as INVOcell™, together with the retention device and any other applicable accessories to market, promote, distribute and sell the Licensed Product with respect to all therapeutic, prophylactic and diagnostic uses of medical devices or pharmaceutical products involving reproductive technology (including infertility treatment) in humans (the “Field”). Ferring is responsible, at its own cost, for all commercialization activities for the Licensed Product in the Field in the United States. The Company does retain a limited exception to the exclusive license granted to Ferring allowing the Company, subject to certain restrictions, to establish up to five clinics that will commercialize INVO cycles in the United States. The Company retains all commercialization rights for the Licensed Product outside of the United States. (B) Basis of Presentation (Share Exchange and Corporate Structure) On December 5, 2008, the Company completed a share exchange with Emy’s Salsa Aji Distribution Company, Inc. (“Emy’s”), a publicly registered shell corporation with no significant assets or operations. Emy’s was incorporated on July 11, 2005, under the laws of the State of Nevada under the name Certiorari Corp. In connection with the share exchange, INVO Bioscience became Emy’s wholly-owned subsidiary and the INVO Bioscience shareholders acquired control of Emy’s. The Company accounted for the transaction as a recapitalization and the Company is the surviving entity. In connection with the share exchange, Emy’s shareholders retained 14,937,500 shares. Effective with the Agreement, all previously outstanding shares of Common Stock owned by the Company’s shareholders were exchanged for an aggregate of 38,307,500 shares of Emy’s common stock. Effective with the Agreement, Emy’s changed its name to INVO Bioscience, Inc. All references to “Common Stock,” “share” and “per share” amounts have been retroactively restated to reflect the exchange ratio of 357.0197 shares of INVO Bioscience Common Stock for one share of Emy’s common stock outstanding immediately prior to the merger as if the exchange had taken place as of the beginning of the earliest period presented. The accompanying consolidated financial statements present the historical financial condition, results of operations and cash flows of the Company prior to the merger with Emys. The accompanying consolidated financial statements present on a consolidated basis the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. (C) Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. (D) Cash and Cash Equivalents The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. The Company had the amounts of cash and cash equivalents on its balance sheets as of December 31, 2018 and 2017 of $212,243 and $25,759, respectively. (E) Inventory Inventories consist of work in process (WIP) and finished products and are stated at the lower of cost or market; using the first-in, first-out (FIFO) method as a cost flow convention. (F) Property and Equipment The Company records property and equipment at cost. Depreciation and amortization are provided using the straight-line method over the estimated economic lives of the assets, which are from 3 to 7 years. The Company capitalizes the expenditures for major renewals and improvements that extend the useful lives of property and equipment. Expenditures for maintenance and repairs are charged to expense as incurred. The Company reviews the carrying value of long-lived assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by a comparison of its carrying amount to the undiscounted cash flows that the asset or asset group is expected to generate. If such assets are considered impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the property, if any, exceeds its fair market value. (G) Stock Based Compensation The Company accounts for stock-based compensation under the provisions of Accounting Standards Codification subtopic 718-10, Compensation (“ASC 718-10”). This statement requires the Company to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period in which the employee is required to provide service in exchange for the award, which is usually the vesting period. ( H) Loss Per Share Basic loss per share calculations are computed by dividing income (loss) available to common shareholders by the weighted-average number of common shares outstanding. Diluted earnings per share is computed similar to basic earnings per share except that the denominator is increased to include securities or other contracts to issue common stock that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company’s diluted loss per share is the same as the basic loss per share for the years ended December 31, 2018 and 2017, as the inclusion of any potential shares would have had an anti-dilutive effect due to the Company generating a loss. Twelve Months Ended December 31, 2018 2017 Loss to common shareholders (Numerator) $ (3,076,091 ) $ (702,163 ) Basic and diluted weighted-average number of common shares outstanding (Denominator) 147,333,051 141,305,050 The Company has excluded the following dilutive securities from the calculation of fully-diluted shares outstanding because the result would have been anti-dilutive: Twelve Months Ended December 31, 2018 2017 Effect of dilutive common stock equivalents: Convertible notes and interest 6,020,200 3,391,300 Total 6,020,200 3,391,300 ( I) Fair Value of Financial Instruments ASC 825-10-50, “Disclosures about Fair Value of Financial Instruments,” (formerly SFAS No. 107) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. Effective January 1, 2008, the Company adopted ASC 820-10, “Fair Value Measurements” (SFAS 157), which provides a framework for measuring fair value under GAAP. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 requires that valuation techniques maximize the use of observable inputs and minimize the use of unobservable inputs. (J) Income Taxes The Company accounts for income taxes under the ASC 740-10-05, “Accounting for Income Taxes” (SFAS 109). Under ASC 740-10, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740-10, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. On December 22, 2017, the Tax Cuts and Jobs Act (TCJA) was signed into law by the President of the United States. TCJA is a tax reform act that among other things, reduced corporate tax rates to 21 percent effective January 1, 2018. FASB ASC 740, Income Taxes (K) Business Segments The Company operates in one segment and therefore segment information is not presented. (L) Concentration of Credit Risk Cash includes amounts deposited in financial institutions in excess of insurable Federal Deposit Insurance Corporation (FDIC) limits. As of December 31, 2018, the Company had no cash balances in excess of FDIC limits. (M) Revenue Recognition The Company will recognize revenue on arrangements in accordance with ASC 606 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. (N) Long- Lived Assets Long-lived assets and certain identifiable assets related to those assets are periodically reviewed for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may not be recoverable. If the non-discounted future cash flows of the enterprise are less than their carrying amount, their carrying amounts are reduced to the fair value and an impairment loss recognized. There was no impairment recorded from January 5, 2007 (inception) to December 31, 2018. (O) Reclassifications Certain reclassifications have been made in prior year’s financial statements to conform to classifications used in the current year. (P) Recent Accounting Pronouncements In May 2014, the FASB issued ASC 606, Revenue from Contracts with Customers (“ASC 606”). The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The standard is effective for annual periods beginning after December 15, 2017, and interim periods therein. ASU 2014-09 supersedes existing guidance on revenue recognition with a five-step model for recognizing and measuring revenue from contracts with customers. The objective of the new standard is to provide a single, comprehensive revenue recognition model for all contracts with customers to improve comparability within industries, across industries, and across capital markets. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The guidance also requires a number of disclosures regarding the nature, amount, timing, and uncertainty of revenue and the related cash flows. The guidance can be applied retrospectively to each prior reporting period presented (full retrospective method) or retrospectively with a cumulative effect adjustment to retained earnings for initial application of the guidance at the date of initial adoption (modified retrospective method). The Company adopted the new standard effective January 1, 2018 using the modified retrospective method applied to those contracts that were not completed or substantially completed as of January 1, 2018. The timing and measurement of revenue recognition under the new standard is not materially different than under the old standard. The adoption of the new standard did not have an impact on the Company’s consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230) (“ASU 2016-15”). The updated standard addresses eight specific cash flow issues with the objective of reducing diversity in practice. ASU 2016-15 is effective for public business entities for annual reporting periods beginning after December 15, 2017, including interim periods within those annual reporting periods. Early adoption is permitted. The Company adopted ASU 2016-15 as of January 1, 2018. The adoption of ASU 2016-15 did not have an impact on the Company’s consolidated financial statements. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230) (“ASU 2016-18”). The updated standard requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 is effective for public business entities for annual reporting periods beginning after December 15, 2017, including interim periods within those annual reporting periods. The Company adopted ASU 2016-18 as of January 1, 2018. The adoption of ASU 2016-18 did not have a material effect on the Company’s consolidated financial statements. In May 2017, the FASB issued ASU 2017-09, Compensation – Stock Compensation (Topic 718) (“ASU 2017-09”). The updated standard clarifies when an entity must apply modification accounting to changes in the terms or conditions of a share-based payment award. ASU 2017-09 is effective for public business entities for annual reporting periods beginning after December 15, 2017, including interim periods within those annual reporting periods. Early adoption is permitted. The Company adopted ASU 2017-09 as of January 1, 2018. The adoption of ASU 2017-09 did not have a material effect on the Company’s consolidated financial statements. In February 2016, FASB issued ASU 2016-02, Leases (“ASU 2016-02”). The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact of its pending adoption of ASU 2016-02 on its consolidated financial statements. In July 2017, FASB issued ASU 2017-11 (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception (“ASU 2017-11”). The new standard simplifies the accounting for certain financial instruments with down round features. Part I of ASU 2017-11 changes the classification analysis of certain equity-linked financial instruments, such as warrants and embedded conversion features, such that a down round feature is disregarded when assessing whether the instrument is indexed to an entity’s own stock under Subtopic 815-40, Contracts in Entity’s Own Equity. As a result, a down round feature, by itself, no longer requires an instrument to be re-measured at fair value through earnings each period, although all other aspects of the indexation guidance under Subtopic 815-40 continue to apply. Part II of ASU 2017-11 re-characterizes the indefinite deferral of certain provisions of Topic 480, Distinguishing Liabilities from Equity, (currently presented as pending content in the Codification) as a scope exception. No change in practice is expected as a result of these amendments. The new standard is effective for fiscal years beginning after December 15, 2018, early adoption is permitted. The amendments in Part II have no accounting impact and therefore do not have an associated effective date. The Company decided to early adopt this ASU 2017-11 and applied it to the convertible notes it issued during the quarter which are reflected in this Form 10Q. Management was not aware of any accounting issued, but not yet effective accounting standards, if currently adopted would have material effect on the consolidated financial statements.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	NOTE 10 INCOME TAXES The Company has adopted ASC 740-10, which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The Company’s total deferred tax liabilities, deferred tax assets, and deferred tax asset valuation allowances are as of December 31 are as follows: December 31, 2018 December 31, 2017 Total deferred tax assets $ 4,124,000 $ 3,730,000 Less valuation allowance (4,124,000 ) (3,730,000 ) Total deferred tax liabilities - - Net deferred tax asset (liability) $ - $ - Those amounts have been presented in the company’s financial statements as of December 31, as follows: December 31, 2018 2017 Deferred tax asset $ - $ - Deferred tax liability - - Net deferred tax asset (liability) $ - $ - The company has a loss carry forward of $9.6 million that may be offset against future taxable income. On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cut and Jobs Act (the “Tax Act”). The Tax Act establishes new tax laws that affects 2018 and future years, including a reduction in the U.S. federal corporate income tax rate to 21%, effective January 1, 2018. For certain deferred tax assets and deferred tax liabilities, we have recorded a provisional decrease of $1,680,000, with a corresponding net adjustment to valuation allowance of $1,680,000 as of December 31, 2017. Realization of deferred tax assets is dependent on future earnings, if any, the timing and amount of which is uncertain. Those amounts are therefore presented on the Company’s balance sheets as a non-current asset. Utilization of the net operating loss carry forwards may be subject to substantial annual limitations, which may result in the expiration of net operating loss carry forwards before utilization.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation (Share Exchange and Corporate Structure) On December 5, 2008, the Company completed a share exchange with Emy’s Salsa Aji Distribution Company, Inc. (“Emy’s”), a publicly registered shell corporation with no significant assets or operations. Emy’s was incorporated on July 11, 2005, under the laws of the State of Nevada under the name Certiorari Corp. In connection with the share exchange, INVO Bioscience became Emy’s wholly-owned subsidiary and the INVO Bioscience shareholders acquired control of Emy’s. The Company accounted for the transaction as a recapitalization and the Company is the surviving entity. In connection with the share exchange, Emy’s shareholders retained 14,937,500 shares. Effective with the Agreement, all previously outstanding shares of Common Stock owned by the Company’s shareholders were exchanged for an aggregate of 38,307,500 shares of Emy’s common stock. Effective with the Agreement, Emy’s changed its name to INVO Bioscience, Inc. All references to “Common Stock,” “share” and “per share” amounts have been retroactively restated to reflect the exchange ratio of 357.0197 shares of INVO Bioscience Common Stock for one share of Emy’s common stock outstanding immediately prior to the merger as if the exchange had taken place as of the beginning of the earliest period presented. The accompanying consolidated financial statements present the historical financial condition, results of operations and cash flows of the Company prior to the merger with Emys. The accompanying consolidated financial statements present on a consolidated basis the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. The Company had the amounts of cash and cash equivalents on its balance sheets as of December 31, 2018 and 2017 of $212,243 and $25,759, respectively.
Inventory, Policy [Policy Text Block]	Inventory Inventories consist of work in process (WIP) and finished products and are stated at the lower of cost or market; using the first-in, first-out (FIFO) method as a cost flow convention.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment The Company records property and equipment at cost. Depreciation and amortization are provided using the straight-line method over the estimated economic lives of the assets, which are from 3 to 7 years. The Company capitalizes the expenditures for major renewals and improvements that extend the useful lives of property and equipment. Expenditures for maintenance and repairs are charged to expense as incurred. The Company reviews the carrying value of long-lived assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by a comparison of its carrying amount to the undiscounted cash flows that the asset or asset group is expected to generate. If such assets are considered impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the property, if any, exceeds its fair market value.
Share-based Payment Arrangement [Policy Text Block]	Stock Based Compensation The Company accounts for stock-based compensation under the provisions of Accounting Standards Codification subtopic 718-10, Compensation (“ASC 718-10”). This statement requires the Company to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period in which the employee is required to provide service in exchange for the award, which is usually the vesting period.
Earnings Per Share, Policy [Policy Text Block]	Loss Per Share Basic loss per share calculations are computed by dividing income (loss) available to common shareholders by the weighted-average number of common shares outstanding. Diluted earnings per share is computed similar to basic earnings per share except that the denominator is increased to include securities or other contracts to issue common stock that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company’s diluted loss per share is the same as the basic loss per share for the years ended December 31, 2018 and 2017, as the inclusion of any potential shares would have had an anti-dilutive effect due to the Company generating a loss. Twelve Months Ended December 31, 2018 2017 Loss to common shareholders (Numerator) $ (3,076,091 ) $ (702,163 ) Basic and diluted weighted-average number of common shares outstanding (Denominator) 147,333,051 141,305,050 The Company has excluded the following dilutive securities from the calculation of fully-diluted shares outstanding because the result would have been anti-dilutive: Twelve Months Ended December 31, 2018 2017 Effect of dilutive common stock equivalents: Convertible notes and interest 6,020,200 3,391,300 Total 6,020,200 3,391,300
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments ASC 825-10-50, “Disclosures about Fair Value of Financial Instruments,” (formerly SFAS No. 107) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. Effective January 1, 2008, the Company adopted ASC 820-10, “Fair Value Measurements” (SFAS 157), which provides a framework for measuring fair value under GAAP. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 requires that valuation techniques maximize the use of observable inputs and minimize the use of unobservable inputs.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes under the ASC 740-10-05, “Accounting for Income Taxes” (SFAS 109). Under ASC 740-10, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740-10, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. On December 22, 2017, the Tax Cuts and Jobs Act (TCJA) was signed into law by the President of the United States. TCJA is a tax reform act that among other things, reduced corporate tax rates to 21 percent effective January 1, 2018. FASB ASC 740, Income Taxes
Segment Reporting, Policy [Policy Text Block]	Business Segments The Company operates in one segment and therefore segment information is not presented.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk Cash includes amounts deposited in financial institutions in excess of insurable Federal Deposit Insurance Corporation (FDIC) limits. As of December 31, 2018, the Company had no cash balances in excess of FDIC limits.
Revenue [Policy Text Block]	Revenue Recognition The Company will recognize revenue on arrangements in accordance with ASC 606 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services.
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Long- Lived Assets Long-lived assets and certain identifiable assets related to those assets are periodically reviewed for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may not be recoverable. If the non-discounted future cash flows of the enterprise are less than their carrying amount, their carrying amounts are reduced to the fair value and an impairment loss recognized. There was no impairment recorded from January 5, 2007 (inception) to December 31, 2018.
Reclassification, Policy [Policy Text Block]	Reclassifications Certain reclassifications have been made in prior year’s financial statements to conform to classifications used in the current year.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In May 2014, the FASB issued ASC 606, Revenue from Contracts with Customers (“ASC 606”). The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The standard is effective for annual periods beginning after December 15, 2017, and interim periods therein. ASU 2014-09 supersedes existing guidance on revenue recognition with a five-step model for recognizing and measuring revenue from contracts with customers. The objective of the new standard is to provide a single, comprehensive revenue recognition model for all contracts with customers to improve comparability within industries, across industries, and across capital markets. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The guidance also requires a number of disclosures regarding the nature, amount, timing, and uncertainty of revenue and the related cash flows. The guidance can be applied retrospectively to each prior reporting period presented (full retrospective method) or retrospectively with a cumulative effect adjustment to retained earnings for initial application of the guidance at the date of initial adoption (modified retrospective method). The Company adopted the new standard effective January 1, 2018 using the modified retrospective method applied to those contracts that were not completed or substantially completed as of January 1, 2018. The timing and measurement of revenue recognition under the new standard is not materially different than under the old standard. The adoption of the new standard did not have an impact on the Company’s consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230) (“ASU 2016-15”). The updated standard addresses eight specific cash flow issues with the objective of reducing diversity in practice. ASU 2016-15 is effective for public business entities for annual reporting periods beginning after December 15, 2017, including interim periods within those annual reporting periods. Early adoption is permitted. The Company adopted ASU 2016-15 as of January 1, 2018. The adoption of ASU 2016-15 did not have an impact on the Company’s consolidated financial statements. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230) (“ASU 2016-18”). The updated standard requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 is effective for public business entities for annual reporting periods beginning after December 15, 2017, including interim periods within those annual reporting periods. The Company adopted ASU 2016-18 as of January 1, 2018. The adoption of ASU 2016-18 did not have a material effect on the Company’s consolidated financial statements. In May 2017, the FASB issued ASU 2017-09, Compensation – Stock Compensation (Topic 718) (“ASU 2017-09”). The updated standard clarifies when an entity must apply modification accounting to changes in the terms or conditions of a share-based payment award. ASU 2017-09 is effective for public business entities for annual reporting periods beginning after December 15, 2017, including interim periods within those annual reporting periods. Early adoption is permitted. The Company adopted ASU 2017-09 as of January 1, 2018. The adoption of ASU 2017-09 did not have a material effect on the Company’s consolidated financial statements. In February 2016, FASB issued ASU 2016-02, Leases (“ASU 2016-02”). The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact of its pending adoption of ASU 2016-02 on its consolidated financial statements. In July 2017, FASB issued ASU 2017-11 (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception (“ASU 2017-11”). The new standard simplifies the accounting for certain financial instruments with down round features. Part I of ASU 2017-11 changes the classification analysis of certain equity-linked financial instruments, such as warrants and embedded conversion features, such that a down round feature is disregarded when assessing whether the instrument is indexed to an entity’s own stock under Subtopic 815-40, Contracts in Entity’s Own Equity. As a result, a down round feature, by itself, no longer requires an instrument to be re-measured at fair value through earnings each period, although all other aspects of the indexation guidance under Subtopic 815-40 continue to apply. Part II of ASU 2017-11 re-characterizes the indefinite deferral of certain provisions of Topic 480, Distinguishing Liabilities from Equity, (currently presented as pending content in the Codification) as a scope exception. No change in practice is expected as a result of these amendments. The new standard is effective for fiscal years beginning after December 15, 2018, early adoption is permitted. The amendments in Part II have no accounting impact and therefore do not have an associated effective date. The Company decided to early adopt this ASU 2017-11 and applied it to the convertible notes it issued during the quarter which are reflected in this Form 10Q. Management was not aware of any accounting issued, but not yet effective accounting standards, if currently adopted would have material effect on the consolidated financial statements.

Inventory (Tables)

Inventory (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	As of June 30, 2019, and December 31, 2018, the Company recorded the following inventory balances: June 30, 2019 December 31, 2018 Work in Process $ 71,469 $ 30,689 Finished Goods 5,006 12,824 Total Inventory, net $ 76,475 $ 43,513	The Company had inventory in the following amounts: December 31, 2018 December 31, 2017 Work in Process $ 30,689 $ 24,357 Finished Goods 12,824 34,522 Total Inventory $ 43,513 $ 58,879

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Property and Equipment (Tables) [Line Items]
Property, Plant and Equipment [Table Text Block]	June 30, 2019 December 31, 2018 Manufacturing Equipment- Molds $ 132,513 $ 70,363 Office Equipment 2,689 - Accumulated Depreciation (37,093 ) (35,917 ) Total $ 98,109 $ 34,446	December 31, 2018 December 31, 2017 Manufacturing Equipment- Molds $ 70,363 $ 50,963 Accumulated Depreciation (35,917 ) (35,263 ) $ 34,446 $ 15,700
Estimated Useful Life [Member]
Property and Equipment (Tables) [Line Items]
Property, Plant and Equipment [Table Text Block]	The estimated useful lives and accumulated depreciation for furniture, equipment and software are as follows as of June 30, 2019 and December 31, 2018: Estimated Useful Life Molds and Office Equipment 3 to 10 years	The estimated useful lives and accumulated depreciation for furniture, equipment and software are as follows: Estimated Useful Life Molds 3 to 7 years

Patents (Tables)

Patents (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Disclosure Text Block [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	As of June 30, 2019, and December 31, 2018, the Company recorded the following patent balances: June 30, 2019 December 31, 2018 Total Patents $ 77,722 $ 77,743 Accumulated Amortization (68,220 ) (65,951 ) Patent costs, net $ 9,502 $ 11,792	The Company has recorded the following patent costs: December 31, 2018 December 31, 2017 Total Patents $ 77,743 $ 77,743 Accumulated Amortization (65,951 ) (61,415 ) Patent costs, net $ 11,792 $ 16,328
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Estimated amortization expense as of June 30, 2019 is as follows: Years ended December 31, 2019 – remaining six months $ 2,268 2020 1,809 2021 1,809 2022 and thereafter 3,616 Total $ 9,502	Estimated amortization expense as of December 31, 2018 is as follows: Years ended December 31, 2019 $ 4,536 2020 1,809 2021 1,809 2022 1,809 2023 and thereafter 1,829 Total $ 11,792
Finite-lived Intangible Assets Amortization Expense [Table Text Block]		The Company recorded amortization expense as follows: Twelve Months Ended December 31, 2018 2017 $ 4,536 $ 2,810

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2019
Disclosure Text Block [Abstract]
Lessee, Operating Lease, Disclosure [Table Text Block]	As of June 30, 2019, the Company's lease components included in the consolidated balance sheet were as follows: Lease component Classification June 30, 2019 Assets ROU assets - operating lease Other assets $ 112,827 Total ROU assets $ 112,827 Liabilities Current operating lease liability Current liabilities $ 18,898 Long-term operating lease liability Other liabilities 94,173 Total lease liabilities $ 113,071
Lease, Cost [Table Text Block]	Rent expense is recognized on a straight-line basis over the life of the lease. Rent expense consists of the following: Six months ended June 30, 2019 Operating lease costs $ 4,192 Short term lease cost 3,000 Total rent expense $ 7,192
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Future minimum lease payments under non-cancellable leases were as follows: June 30, 2019 2019 - remaining 6 months $ 11,844 2020 24,161 2021 24,886 2022 25,633 2023 26,402 2024 and beyond 8,886 Total future minimum lease payments $ 121,812 Less: Interest 8,741 Total operating lease liabilities $ 113,071 Current operating lease liability $ 18,898 Long-term operating lease liability 94,173 Total operating lease liabilities $ 113,071

Notes Payable and Other Relat_2

Notes Payable and Other Related Party Transactions (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Related Party Transactions [Abstract]
Schedule of Related Party Transactions [Table Text Block]	Principal balances of the Related Party loans were as follows: June 30, 2019 December 31, 2018 James Bowdring Family - 2011 Notes 35,000 35,000 James Bowdring Family – 2018 Convertible Notes 44,161 40,000 Kathleen Karloff Note - 62,743 Less discount (24,089 ) (30,913 ) Total, net of discount $ 55,072 $ 106,830	Principal balances of the Related Party loans were as follows: December 31, 2018 December 31, 2017 Claude Ranoux Note $ - $ 21,888 James Bowdring Family - 2011 Notes 35,000 35,000 James Bowdring Family – 2018 Convertible Notes 40,000 - Kathleen Karloff Note 62,743 154,000 Less discount (30,913 ) - Total, net of discount $ 106,830 $ 210,888
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Accounts payable and accrued liabilities balances include expenses reports for Ms. Karloff and Mr. Bowdring for expenses they paid for personally related to travel or normal business expenses. June 30, December 31, 2019 2018 Accounts payable and accrued liabilities $ 3,702 $ 1,700	Accounts payable and accrued liabilities balances include expenses reports for Ms. Karloff, and Mr. Bowdring for expenses they paid for personally related to travel or normal business expenses and are represented in the following table: December 31, 2018 2017 Accounts payable and accrued liabilities $ 1,700 $ 38,000

Contracts with Customers (Table

Contracts with Customers (Tables)	6 Months Ended
	Jun. 30, 2019
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue [Table Text Block]	We have identified the following revenues disaggregated by revenue source: June 30, 2019 June 30, 2018 Domestic Product revenue $ 490,927 $ 214,350 Domestic licensing fee 357,143 - Total revenue $ 848,070 $ 214,350

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Tables)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The Company’s diluted loss per share is the same as the basic loss per share for the years ended December 31, 2018 and 2017, as the inclusion of any potential shares would have had an anti-dilutive effect due to the Company generating a loss. Twelve Months Ended December 31, 2018 2017 Loss to common shareholders (Numerator) $ (3,076,091 ) $ (702,163 ) Basic and diluted weighted-average number of common shares outstanding (Denominator) 147,333,051 141,305,050
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The Company has excluded the following dilutive securities from the calculation of fully-diluted shares outstanding because the result would have been anti-dilutive: Twelve Months Ended December 31, 2018 2017 Effect of dilutive common stock equivalents: Convertible notes and interest 6,020,200 3,391,300 Total 6,020,200 3,391,300

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The Company’s total deferred tax liabilities, deferred tax assets, and deferred tax asset valuation allowances are as of December 31 are as follows: December 31, 2018 December 31, 2017 Total deferred tax assets $ 4,124,000 $ 3,730,000 Less valuation allowance (4,124,000 ) (3,730,000 ) Total deferred tax liabilities - - Net deferred tax asset (liability) $ - $ -
Schedule of Deferred Tax Assets and Liabilities Reported in Financial Statements [Table Text Block]	Those amounts have been presented in the company’s financial statements as of December 31, as follows: December 31, 2018 2017 Deferred tax asset $ - $ - Deferred tax liability - - Net deferred tax asset (liability) $ - $ -

Going Concern (Details)

Going Concern (Details) - USD ($)	Jan. 14, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Proceeds from License Fees Received	$ 5,000,000			$ 5,000,000
Net Income (Loss) Attributable to Parent		$ (241,552)	$ (1,865,128)	(700,122)	$ (2,009,851)	$ (3,076,091)	$ (702,163)
Net Cash Provided by (Used in) Operating Activities				2,710,232	(249,503)	(652,971)	(181,270)
Working Capital (Deficit)						(2,770,000)
Stockholders' Equity Attributable to Parent		$ (3,159,022)	$ (4,133,499)	$ (3,159,022)	$ (4,133,499)	$ (2,724,223)	$ (4,992,112)	$ (3,102,470)	$ (4,908,171)	$ (4,617,646)

Inventory (Details) - Schedule

Inventory (Details) - Schedule of Inventory, Current - USD ($)	Jun. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Schedule of Inventory, Current [Abstract]
Work in Process	$ 71,469	$ 30,689	$ 24,357
Finished Goods	5,006	12,824	34,522
Total Inventory, net	$ 76,475	$ 43,513	$ 58,879

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Depreciation	$ 39	$ 0	$ 1,176	$ 0	$ 654	$ 0

Property and Equipment (Detai_2

Property and Equipment (Details) - Property, Plant and Equipment	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	3 years	3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	10 years	7 years

Property and Equipment (Detai_3

Property and Equipment (Details) - Property, Plant and Equipment - USD ($)	Jun. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Accumulated Depreciation	$ (37,093)	$ (35,917)
Total	98,109	34,446	$ 15,700
Tools, Dies and Molds [Member]
Property, Plant and Equipment [Line Items]
Manufacturing Equipment- Molds	132,513	70,363	50,963
Accumulated Depreciation		(35,917)	$ (35,263)
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Manufacturing Equipment- Molds	$ 2,689	$ 0

Patents (Details)

Patents (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Sep. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Disclosure Text Block [Abstract]
Amortization of Intangible Assets	$ 1,455	$ 1,134	$ 2,269	$ 2,268

Patents (Details) - Schedule of

Patents (Details) - Schedule of Finite-Lived Intangible Assets - USD ($)	Jun. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Schedule of Finite-Lived Intangible Assets [Abstract]
Total Patents	$ 77,722	$ 77,743	$ 77,743
Accumulated Amortization	(68,220)	(65,951)	(61,415)
Patent costs, net	$ 9,502	$ 11,792	$ 16,328

Patents (Details) - Schedule _2

Patents (Details) - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense - USD ($)	Jun. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Abstract]
2019 – remaining six months	$ 2,268
2020	1,809	$ 1,809
2021	1,809	1,809
2022 and thereafter	3,616	1,829
Total	$ 9,502	$ 11,792	$ 16,328

Leases (Details)

Leases (Details)	Jun. 30, 2019
Disclosure Text Block [Abstract]
Lessee, Operating Lease, Renewal Term	3 years

Leases (Details) - Lessee, Oper

Leases (Details) - Lessee, Operating Lease, Disclosure - USD ($)	Jun. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Assets
ROU assets - operating lease	$ 112,827	$ 0	$ 0
Total ROU assets	112,827
Liabilities
Current operating lease liability	18,898	0	0
Long-term operating lease liability	94,173	$ 0	$ 0
Total lease liabilities	$ 113,071

Leases (Details) - Lease, Cost

Leases (Details) - Lease, Cost	6 Months Ended
	Jun. 30, 2019USD ($)
Lease, Cost [Abstract]
Operating lease costs	$ 4,192
Short term lease cost	3,000
Total rent expense	$ 7,192

Leases (Details) - Lessee, Op_2

Leases (Details) - Lessee, Operating Lease, Liability, Maturity - USD ($)	Jun. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Lessee, Operating Lease, Liability, Maturity [Abstract]
2019 - remaining 6 months	$ 11,844
2020	24,161
2021	24,886
2022	25,633
2023	26,402
2024 and beyond	8,886
Total future minimum lease payments	121,812
Less: Interest	8,741
Total operating lease liabilities	113,071
Current operating lease liability	18,898	$ 0	$ 0
Long-term operating lease liability	$ 94,173	$ 0	$ 0

Notes Payable (Details)

Notes Payable (Details)	May 31, 2018USD ($)$ / shares	May 31, 2019USD ($)shares	Apr. 30, 2019USD ($)shares	Feb. 28, 2019USD ($)shares	Dec. 31, 2018USD ($)shares	Nov. 30, 2018USD ($)shares	May 31, 2018USD ($)$ / shares	Mar. 31, 2017USD ($)shares	Aug. 31, 2016USD ($)	Jun. 30, 2019USD ($)	Dec. 31, 2018USD ($)shares	Jun. 30, 2018USD ($)	Jun. 30, 2019USD ($)shares	Jun. 30, 2018USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2009USD ($)$ / sharesshares	May 31, 2015USD ($)	May 31, 2010USD ($)
Notes Payable (Details) [Line Items]
Debt Conversion, Original Debt, Amount		$ 25,000	$ 160,000	$ 53,723	$ 158,667	$ 52,416							$ 238,723	$ 0	$ 211,083	$ 57,940
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | shares		125,000	800,000	268,615	793,335	262,080
Convertible Notes Payable										$ 16,550			16,550
Amortization of Debt Discount (Premium)													256,703	56,446	366,126	0
Debt Instrument, Unamortized Discount					$ 30,913					24,089	$ 30,913		24,089		30,913	0
Debt Instrument, Face Amount	$ 40,000						$ 40,000
Debt Instrument, Interest Rate, Stated Percentage	9.00%						9.00%
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares	$ 0.20						$ 0.20
Debt Instrument, Convertible, Terms of Conversion Feature							The notes are convertible into shares of common stock at a price of $0.20 per share, provided, that if the Company completes a subsequent equity financing, the holders of the 2018 Convertible Notes can elect to convert the notes in shares of our common stock at a price equal to 75% of the price paid per share in such subsequent equity financing
Debt Instrument, Convertible, Beneficial Conversion Feature												$ 895,000		895,000	895,000	0
Gain (Loss) on Extinguishment of Debt								$ (40,869)		0		0	0	0	0	(40,869)
Converted Account Payable to Promissory Note [Member]
Notes Payable (Details) [Line Items]
Interest Expense, Debt										0		1,647	489	3,293
Repayments of Convertible Debt													9,823
Debt Instrument, Face Amount									$ 131,722
Debt Instrument, Interest Rate, Stated Percentage									5.00%
Debt Instrument, Term									3 years
The 2018 Convertible Notes [Member]
Notes Payable (Details) [Line Items]
Interest Expense, Debt													26,445	14,343	53,564
Convertible Debt, Current										0			$ 0
Debt Conversion, Original Debt, Amount											$ 200,000
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | shares											1,055,415		268,615
Convertible Notes Payable												232,960		232,960
Amortization of Debt Discount (Premium)										$ 44,904		56,446			366,126
Amortization of Debt Issuance Costs and Discounts													$ 155,939
Debt Instrument, Unamortized Discount												248,082		248,082
Debt Instrument, Face Amount	$ 895,000						$ 895,000
Debt Instrument, Interest Rate, Stated Percentage	9.00%						9.00%
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares	$ 0.20						$ 0.20
Debt Instrument, Convertible, Terms of Conversion Feature	shares of common stock at a price of $0.20 per share, provided, that if the Company completes a subsequent equity financing, the holders of the 2018 Convertible Notes can elect to convert the notes in shares of our common stock at a price equal to 75% of the price paid per share in such subsequent equity financing
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 895,000
Number of Note Holders											3
Bridge Note [Member]
Notes Payable (Details) [Line Items]
Debt Conversion, Original Debt, Amount								$ 10,000
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | shares								341,000
Gain (Loss) on Extinguishment of Debt								$ (40,869)
Note Payable, Long Time Vendor [Member]
Notes Payable (Details) [Line Items]
Interest Expense, Debt															9,586	6,586
The 2018 Convertible Notes, Due January 30, 2021 [Member]
Notes Payable (Details) [Line Items]
Convertible Notes Payable	550,000						$ 550,000
The 2018 Convertible Notes, Due March 31, 2021 [Member]
Notes Payable (Details) [Line Items]
Convertible Notes Payable	$ 345,000						$ 345,000
Convertible Debt [Member]
Notes Payable (Details) [Line Items]
Convertible Debt, Current					$ 0						$ 0				0	2,018
Convertible Debt [Member] | Bridge Note [Member]
Notes Payable (Details) [Line Items]
Interest Expense, Debt															$ 0	$ 0
Debt Conversion, Original Debt, Amount																		$ 535,000
Debt Instrument, Unamortized Discount																	$ 545,000
Debt Instrument, Face Amount																	$ 545,000
Debt Instrument, Term																	1 year
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares																	$ 0.10
Debt Instrument, Convertible, Terms of Conversion Feature																	If the Company were to issue any new shares of common stock within 24 months of the date of the Bridge Notes at a price below the Original Conversion Price, then the conversion price of the Bridge Notes would be adjusted to reflect the new lower price.
Class of Warrant or Rights, Granted (in Shares) | shares																	5,750,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares																	$ 0.20
Debt Instrument, Convertible, Beneficial Conversion Feature																	$ 1,473,710
Other Noncash Expense																	1,341,884
Debt Instrument, Convertible, Carrying Amount of Equity Component																	1,719,666
Excess Value of Warrant Liability																	1,326,492
Derivative Liability, Current																	$ 2,668,371
Convertible Debt [Member] | Bridge Note [Member] | Minimum [Member]
Notes Payable (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage																	10.00%
Convertible Debt [Member] | Bridge Note [Member] | Maximum [Member]
Notes Payable (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage																	12.00%
Convertible Debt [Member] | Q2 Note [Member]
Notes Payable (Details) [Line Items]
Derivative Liability, Current																			$ 545,000
Discount Related to Beneficial Conversion Feature [Member] | Convertible Debt [Member] | Bridge Note [Member]
Notes Payable (Details) [Line Items]
Debt Instrument, Unamortized Discount																	$ 151,826
Debt Discount Related to Warrants [Member] | Convertible Debt [Member] | Bridge Note [Member]
Notes Payable (Details) [Line Items]
Debt Instrument, Unamortized Discount																	$ 393,174
Principal [Member] | The 2018 Convertible Notes [Member]
Notes Payable (Details) [Line Items]
Debt Conversion, Original Debt, Amount													50,000
Convertible Notes Payable												420,000		420,000
Accrued Interest [Member] | The 2018 Convertible Notes [Member]
Notes Payable (Details) [Line Items]
Debt Conversion, Original Debt, Amount													3,723
Convertible Notes Payable												$ 61,042		$ 61,042
Conversion 2 [Member] | The 2018 Convertible Notes [Member]
Notes Payable (Details) [Line Items]
Debt Conversion, Original Debt, Amount													$ 185,000
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | shares													925,000

Notes Payable and Other Relat_3

Notes Payable and Other Related Party Transactions (Details) - USD ($)	May 31, 2018	Dec. 28, 2009	Mar. 26, 2009	Jan. 31, 2019	May 31, 2018	Apr. 30, 2018	Nov. 30, 2017	Sep. 30, 2017	Jun. 30, 2017	Apr. 30, 2017	Mar. 31, 2017	May 31, 2009	May 31, 2018	Jun. 30, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2011	Nov. 30, 2011	Apr. 30, 2011	Mar. 05, 2009
Notes Payable and Other Related Party Transactions (Details) [Line Items]
Repayments of Related Party Debt																		$ 62,743	$ 28,000	$ 113,145	$ 0
Interest Expense, Related Party														$ 1,770		$ 2,247		3,521	5,039	21,976	11,543
Operating Leases, Rent Expense																		3,000
Due to Related Parties, Current														0				0		9,087	0
Debt Instrument, Interest Rate, Stated Percentage	9.00%				9.00%								9.00%
Debt Instrument, Maturity Date					Mar. 31, 2021
Debt Instrument, Face Amount	$ 40,000				$ 40,000								$ 40,000
Notes Payable, Related Parties														55,072				55,072		106,830	210,888
Debt Instrument, Convertible, Conversion Price (in Dollars per share)	$ 0.20				$ 0.20								$ 0.20
Debt Instrument, Convertible, Terms of Conversion Feature					The notes are convertible into shares of common stock at a price of $0.20 per share, provided, that if the Company completes a subsequent equity financing, the holders of the 2018 Convertible Notes can elect to convert the notes in shares of our common stock at a price equal to 75% of the price paid per share in such subsequent equity financing
Stock Issued During Period, Shares, New Issues (in Shares)					150,000		55,556	262,500
Proceeds from Issuance of Common Stock																		0	47,000	47,000	54,625
Stock Issued During Period, Shares, Issued for Services (in Shares)				60,000	3,020,000	340,000	395,550	133,960	99,412	51,750	196,000		340,000				352,326
Stock Issued During Period, Value, Issued for Services				$ 26,600	$ 1,540,000	$ 174,800	$ 79,215	$ 28,576	$ 30,898	$ 17,201	$ 59,242		$ 174,800			1,714,800	$ 43,664	26,600	1,758,464	1,843,664	215,132
Chief Executive Officer [Member]
Notes Payable and Other Related Party Transactions (Details) [Line Items]
Repayments of Related Party Debt																				91,257	0
Interest Expense, Related Party																				15,278	4,400
Due to Related Parties, Current																									$ 88,000
Debt Instrument, Interest Rate, Stated Percentage																						0.00%						5.00%
Debt Instrument, Maturity Date												Oct. 31, 2018
Debt Instrument, Face Amount																												$ 75,000
Proceeds from Related Party Debt												$ 13,000										$ 66,000
Notes Payable, Related Parties														0				0		62,743	154,000
Chief Executive Officer [Member] | Principal [Member]
Notes Payable and Other Related Party Transactions (Details) [Line Items]
Repayments of Related Party Debt																		62,743
Chief Executive Officer [Member] | Accrued Interest [Member]
Notes Payable and Other Related Party Transactions (Details) [Line Items]
Repayments of Related Party Debt																		44,000
Immediate Family Member of Management or Principal Owner [Member]
Notes Payable and Other Related Party Transactions (Details) [Line Items]
Interest Expense, Related Party														249		249		496	496
Debt Instrument, Interest Rate, Stated Percentage																										10.00%	10.00%
Debt Instrument, Face Amount		$ 100,000																								$ 10,000	$ 50,000
Notes Payable, Related Parties																								$ 25,000
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares)		666,667
Debt Instrument, Convertible, Conversion Price (in Dollars per share)																								$ 0.03		$ 0.01
Immediate Family Member of Management or Principal Owner [Member] | Building [Member]
Notes Payable and Other Related Party Transactions (Details) [Line Items]
Operating Leases, Rent Expense, Minimum Rentals																		600
Operating Leases, Rent Expense														5,256		234		6,034	234	5,600	4,400
Related Party Transaction, Expenses from Transactions with Related Party																				2,130	4,100
President, Director, and Chief Scientific Officer [Member]
Notes Payable and Other Related Party Transactions (Details) [Line Items]
Repayments of Related Party Debt																				21,888	0
Due to Related Parties, Current																					96,462		$ 21,888
Debt Instrument, Interest Rate, Stated Percentage			5.00%
Debt Instrument, Maturity Date			Oct. 31, 2018
Charles Mulrey and Family [Member]
Notes Payable and Other Related Party Transactions (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares)															150,000
Sale of Stock, Price Per Share (in Dollars per share)															$ 0.20
Proceeds from Issuance of Common Stock															$ 30,000
One of Directors, Dr. Kevin Doody [Member] | Restricted Stock [Member]
Notes Payable and Other Related Party Transactions (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services (in Shares)					3,020,000										3,000,000
Stock Issued During Period, Value, Issued for Services					$ 1,540,000										$ 1,530,000
Q2 Note [Member] | Immediate Family Member of Management or Principal Owner [Member]
Notes Payable and Other Related Party Transactions (Details) [Line Items]
Interest Expense, Related Party														623				1,239
The 2018 Convertible Notes [Member]
Notes Payable and Other Related Party Transactions (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	9.00%				9.00%								9.00%
Debt Instrument, Face Amount	$ 895,000				$ 895,000								$ 895,000
Debt Instrument, Convertible, Conversion Price (in Dollars per share)	$ 0.20				$ 0.20								$ 0.20
Debt Instrument, Convertible, Terms of Conversion Feature	shares of common stock at a price of $0.20 per share, provided, that if the Company completes a subsequent equity financing, the holders of the 2018 Convertible Notes can elect to convert the notes in shares of our common stock at a price equal to 75% of the price paid per share in such subsequent equity financing
The 2018 Convertible Notes [Member] | Immediate Family Member of Management or Principal Owner [Member]
Notes Payable and Other Related Party Transactions (Details) [Line Items]
Interest Expense, Related Party														897		$ 562		1,785	$ 562
Notes Payable, Related Parties														$ 44,161				$ 44,161		$ 40,000	$ 0

Notes Payable and Other Relat_4

Notes Payable and Other Related Party Transactions (Details) - Schedule of Related Party Transactions - USD ($)	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2015
Related Party Transaction [Line Items]
Related Party Notes	$ 55,072	$ 106,830		$ 210,888
Less discount	(24,089)	(30,913)		0
Immediate Family Member of Management or Principal Owner [Member]
Related Party Transaction [Line Items]
Related Party Notes					$ 25,000
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Related Party Notes	0	62,743		154,000
2011 Notes [Member] | Immediate Family Member of Management or Principal Owner [Member]
Related Party Transaction [Line Items]
Related Party Notes	35,000	35,000		35,000
The 2018 Convertible Notes [Member]
Related Party Transaction [Line Items]
Less discount			$ (248,082)
The 2018 Convertible Notes [Member] | Immediate Family Member of Management or Principal Owner [Member]
Related Party Transaction [Line Items]
Related Party Notes	$ 44,161	$ 40,000		$ 0

Notes Payable and Other Relat_5

Notes Payable and Other Related Party Transactions (Details) - Schedule of Accounts Payable and Accrued Liabilities - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Schedule of Accounts Payable and Accrued Liabilities [Abstract]
Accounts payable and accrued liabilities	$ 3,702	$ 1,700

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	1 Months Ended															2 Months Ended	3 Months Ended				6 Months Ended		12 Months Ended		67 Months Ended
	May 31, 2019	Apr. 30, 2019	Feb. 28, 2019	Jan. 31, 2019	Dec. 31, 2018	Nov. 30, 2018	Oct. 31, 2018	May 31, 2018	Apr. 30, 2018	Jan. 31, 2018	Nov. 30, 2017	Sep. 30, 2017	Jun. 30, 2017	Apr. 30, 2017	Mar. 31, 2017	May 31, 2018	Jun. 30, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	May 31, 2015
Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services (in Shares)				60,000				3,020,000	340,000		395,550	133,960	99,412	51,750	196,000	340,000				352,326
Stock Issued During Period, Value, Issued for Services				$ 26,600				$ 1,540,000	$ 174,800		$ 79,215	$ 28,576	$ 30,898	$ 17,201	$ 59,242	$ 174,800			$ 1,714,800	$ 43,664	$ 26,600	$ 1,758,464	$ 1,843,664	$ 215,132
Debt Conversion, Converted Instrument, Shares Issued (in Shares)	125,000	800,000	268,615		793,335	262,080
Debt Conversion, Original Debt, Amount	$ 25,000	$ 160,000	$ 53,723		$ 158,667	$ 52,416															238,723	0	211,083	57,940
Stock Issued During Period, Shares, New Issues (in Shares)								150,000			55,556	262,500
Stock Issued During Period, Value, New Issues								$ 30,000			$ 10,000	$ 44,625							30,000			77,000	77,000	54,625
Proceeds from Issuance of Common Stock																					0	47,000	47,000	54,625
Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture (in Shares)					887,306		4,895,076
Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture					$ 349,602		$ 1,914,831
Gain (Loss) on Extinguishment of Debt															$ (40,869)		$ 0		$ 0		$ 0	$ 0	$ 0	$ (40,869)
Restricted Stock [Member] | Management and Board Members [Member]
Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Value, Issued for Services										$ 138,000
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture (in Shares)										1,200,000
Restricted Stock [Member] | One of Directors, Dr. Kevin Doody [Member]
Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services (in Shares)								3,020,000										3,000,000
Stock Issued During Period, Value, Issued for Services								$ 1,540,000										$ 1,530,000
Bridge Note [Member]
Stockholders' Equity (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)															341,000
Debt Conversion, Original Debt, Amount															$ 10,000
Gain (Loss) on Extinguishment of Debt															$ (40,869)
Convertible Debt [Member] | Bridge Note [Member]
Stockholders' Equity (Details) [Line Items]
Debt Conversion, Original Debt, Amount																									$ 535,000
Private Placement [Member]
Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares)																				260,000
Proceeds from Issuance or Sale of Equity																				$ 47,000
Private Placement [Member] | Restricted Stock [Member] | Immediate Family Member of Management or Principal Owner [Member]
Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares)								150,000
Proceeds from Issuance or Sale of Equity								$ 30,000
Investors [Member] | Principal [Member]
Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares)																				260,000
Investors [Member] | Convertible Debt [Member]
Stockholders' Equity (Details) [Line Items]
Proceeds from Issuance of Common Stock																				$ 47,000
Management and Board Members [Member]
Stockholders' Equity (Details) [Line Items]
Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture (in Shares)										1,200,000
Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture										$ 138,000

Contracts with Customers (Detai

Contracts with Customers (Details) - USD ($)	Jan. 14, 2019	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Revenue from Contract with Customer [Abstract]
Proceeds from License Fees Received	$ 5,000,000	$ 5,000,000
Contract With Customer, Term	7 years
Subsequent Licensing Fee Payment	$ 3,000,000
Deferred Revenue, Revenue Recognized		178,571	$ 357,143
Deferred Revenue		$ 4,655,832		$ 18,895
Revenue from Contract with Customer, Including Assessed Tax				$ 61,000

Contracts with Customers (Det_2

Contracts with Customers (Details) - Disaggregation of Revenue - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Disaggregation of Revenue [Line Items]
Revenue	$ 658,638	$ 110,210	$ 848,070	$ 214,350	$ 494,375	$ 282,145
Domestic Physicians [Member]
Disaggregation of Revenue [Line Items]
Revenue			490,927	214,350
Domestic Licensing & Distribution Fee [Member]
Disaggregation of Revenue [Line Items]
Revenue			$ 357,143	$ 0

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] - USD ($)	Aug. 07, 2019	Feb. 28, 2019	Jan. 14, 2019	Jan. 31, 2019
Subsequent Events (Details) [Line Items]
Repayments of Related Party Debt	$ 65,197
Debt Instrument, Interest Rate, Stated Percentage	10.00%
Debt Instrument, Convertible, Conversion Price (in Dollars per share)	$ 0.0065
Proceeds from License Fees Received			$ 5,000,000
Stock Issued During Period, Shares, Issued for Services (in Shares)				60,000
Stock Issued During Period, Value, Issued for Services				$ 26,600
Debt Conversion, Converted Instrument, Shares Issued (in Shares)		268,615
Debt Conversion, Original Debt, Amount		$ 53,168
Minimum [Member]
Subsequent Events (Details) [Line Items]
Debt Instrument, Convertible, Conversion Price (in Dollars per share)	0.03
Maximum [Member]
Subsequent Events (Details) [Line Items]
Debt Instrument, Convertible, Conversion Price (in Dollars per share)	$ 0.01

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Details)	Dec. 22, 2017	Dec. 05, 2008$ / sharesshares	May 31, 2018shares	Nov. 30, 2017shares	Sep. 30, 2017shares	Dec. 31, 2018USD ($)	Jun. 30, 2019USD ($)	Dec. 31, 2017USD ($)
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Details) [Line Items]
Stock Issued During Period, Shares, New Issues			150,000	55,556	262,500
Cash and Cash Equivalents, at Carrying Value | $						$ 212,243	$ 2,663,171	$ 25,759
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%
Number of Reportable Segments						1
Minimum [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Details) [Line Items]
Property, Plant and Equipment, Estimated Useful Lives						3
Maximum [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Details) [Line Items]
Property, Plant and Equipment, Estimated Useful Lives						7 years
Emy's Salsa Aji Distribution Company, Inc. ("Emy's") [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Details) [Line Items]
Share Exchange, Number of Shares Retained		14,937,500
Stock Issued During Period, Shares, New Issues		38,307,500
Share Exchange Ratio | $ / shares		$ 357.0197

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Details) - Schedule of Earnings Per Share, Basic and Diluted - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Schedule of Earnings Per Share, Basic and Diluted [Abstract]
Loss to common shareholders (Numerator)	$ (3,076,091)	$ (702,163)
Basic and diluted weighted-average number of common shares outstanding (Denominator)	147,333,051	141,305,050

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,020,200	3,391,300
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,020,200	3,391,300

INVENTORY (Details) - Schedul_2

INVENTORY (Details) - Schedule of Inventory, Current - USD ($)	Jun. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Schedule of Inventory, Current [Abstract]
Work in Process	$ 71,469	$ 30,689	$ 24,357
Finished Goods	5,006	12,824	34,522
Total Inventory	$ 76,475	$ 43,513	$ 58,879

PROPERTY AND EQUIPMENT (Detai_4

PROPERTY AND EQUIPMENT (Details) - Property, Plant and Equipment, Estimated Useful Life	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Minimum [Member]
Property, Plant and Equipment [Line Items]
Molds	3 years	3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Molds	10 years	7 years

PROPERTY AND EQUIPMENT (Detai_5

PROPERTY AND EQUIPMENT (Details) - Property, Plant and Equipment - USD ($)	Jun. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Accumulated Depreciation	$ (37,093)	$ (35,917)
	98,109	34,446	$ 15,700
Tools, Dies and Molds [Member]
Property, Plant and Equipment [Line Items]
Manufacturing Equipment- Molds	$ 132,513	70,363	50,963
Accumulated Depreciation		$ (35,917)	$ (35,263)

PATENTS (Details) - Schedule _3

PATENTS (Details) - Schedule of Finite-Lived Intangible Assets - USD ($)	Jun. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Schedule of Finite-Lived Intangible Assets [Abstract]
Total Patents	$ 77,722	$ 77,743	$ 77,743
Accumulated Amortization	(68,220)	(65,951)	(61,415)
Patent costs, net	$ 9,502	$ 11,792	$ 16,328

PATENTS (Details) - Finite-live

PATENTS (Details) - Finite-lived Intangible Assets Amortization Expense - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Finite-lived Intangible Assets Amortization Expense [Abstract]
Amortization expense	$ 4,536	$ 2,810

PATENTS (Details) - Schedule _4

PATENTS (Details) - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense - USD ($)	Jun. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Abstract]
2019		$ 4,536
2020	$ 1,809	1,809
2021	1,809	1,809
2022		1,809
2023 and thereafter	3,616	1,829
Total	$ 9,502	$ 11,792	$ 16,328

NOTE PAYABLE AND OTHER RELATED

NOTE PAYABLE AND OTHER RELATED PARTY TRANSACTIONS (Details) - Schedule of Related Party Transactions - USD ($)	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2015
Related Party Transaction [Line Items]
Related Party Loans	$ 55,072	$ 106,830		$ 210,888
Less discount	(24,089)	(30,913)		0
Director [Member]
Related Party Transaction [Line Items]
Related Party Loans		0		21,888
Immediate Family Member of Management or Principal Owner [Member]
Related Party Transaction [Line Items]
Related Party Loans					$ 25,000
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Related Party Loans	0	62,743		154,000
2011 Notes [Member] | Immediate Family Member of Management or Principal Owner [Member]
Related Party Transaction [Line Items]
Related Party Loans	35,000	35,000		35,000
The 2018 Convertible Notes [Member]
Related Party Transaction [Line Items]
Less discount			$ (248,082)
The 2018 Convertible Notes [Member] | Immediate Family Member of Management or Principal Owner [Member]
Related Party Transaction [Line Items]
Related Party Loans	$ 44,161	$ 40,000		$ 0

NOTE PAYABLE AND OTHER RELATE_2

NOTE PAYABLE AND OTHER RELATED PARTY TRANSACTIONS (Details) - Schedule of Accounts Payable and Accrued Liabilities - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Schedule of Accounts Payable and Accrued Liabilities [Abstract]
Accounts payable and accrued liabilities	$ 1,700	$ 38,000

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	Dec. 22, 2017	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Operating Loss Carryforwards						$ 9,600,000
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%
Income Tax Expense (Benefit)	$ (1,680,000)	$ 0	$ 0	$ 0	$ 0
Deferred Tax Assets, Valuation Allowance	$ 1,680,000					$ 4,124,000	$ 3,730,000

INCOME TAXES (Details) - Schedu

INCOME TAXES (Details) - Schedule of Deferred Tax Assets and Liabilities - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Dec. 22, 2017	Dec. 31, 2016
Schedule of Deferred Tax Assets and Liabilities [Abstract]
Total deferred tax assets	$ 4,124,000	$ 3,730,000
Less valuation allowance	(4,124,000)	(3,730,000)	$ (1,680,000)
Total deferred tax liabilities	0	0
Net deferred tax asset (liability)	$ 0	$ 0		$ 0

INCOME TAXES (Details) - Sche_2

INCOME TAXES (Details) - Schedule of Deferred Tax Assets and Liabilities Reported in Financial Statements - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Schedule of Deferred Tax Assets and Liabilities Reported in Financial Statements [Abstract]
Deferred tax asset		$ 0	$ 0
Deferred tax liability		0	0
Net deferred tax asset (liability)	$ 0	$ 0	$ 0